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ABSTRACT 
Background. Dehydroepiandrosterone (DHEA) and its sulfated form 
DHEA sulfate (DHEAS) are the most abundant steroid hormones in the 
circulation. These prohormones, secreted by the adrenal glands, are 
important precursors of biologically active androgens and estrogens. Adipose 
tissue is a major site for estrogen synthesis after menopause, when all 
estrogens are produced from hormone precursors in peripheral tissues. In 
the circulation, DHEA exists also as fatty acyl esters. These lipophilic 
derivatives of DHEA are transported by circulating lipoprotein particles and 
can be internalized and metabolized by peripheral tissues. DHEA and high-
density lipoprotein (HDL) are both vascular relaxants. The aims were to 
study the role of DHEA fatty acyl esters in the HDL-mediated vasodilation, to 
study the cellular uptake and metabolism of HDL-associated DHEA fatty acyl 
esters in endothelial cells, and to investigate the metabolism of DHEAS in 
adipose tissue obtained from pre- and postmenopausal women. 
Methods. To incorporate DHEA or [3H]DHEA fatty acyl esters in 
lipoproteins, DHEA or [3H]DHEA was incubated with human plasma, in the 
presence and absence of lecithin:cholesterol acyltransferase (LCAT) 
inhibitor, and lipoproteins were isolated and purified. The radioactivity 
associated with lipoproteins was analyzed by thin-layer chromatography.  
Isolated rings of rat mesenteric arteries were precontracted with 
noradrenaline, and the relaxation responses were measured after the 
addition of increasing concentrations of native HDL, DHEA fatty acyl ester-
enriched HDL, or HDL from the plasma incubation with DHEA and LCAT 
inhibitor. Selected experiments were carried out in rings pretreated with the 
inhibitors of endothelial nitric oxide synthase (eNOS), scavenger receptor 
class B, type I (SR-BI), androgen receptor, or estrogen receptors. 
Human umbilical vein endothelial cells were treated with [3H]DHEA fatty 
acyl ester-enriched HDL, and the radioactivity in the cellular and 
extracellular fractions was analyzed by thin-layer chromatography. The 
phosphorylation of eNOS in endothelial cells was analyzed by Western blot 
after treatment of the cells with DHEA fatty acyl ester-enriched HDL. 
In adipose tissue obtained from pre- and postmenopausal women, steroid 
sulfatase activity was measured as the conversion of [3H]DHEAS to 
[3H]DHEA, and mRNA expression levels of steroid-converting enzyme genes 
were determined by quantitative real-time RT-PCR. 
Results. DHEA became esterified and associated with lipoproteins 
during the incubation with plasma. The esterification was dependent on 
LCAT. DHEA fatty acyl ester-enriched HDL caused a dose-dependent arterial 
relaxation (mean, maximal 43%). This response was significantly stronger 
than the responses to native HDL (25%) and to HDL from the plasma 
incubation of DHEA in the presence of LCAT inhibitor (25%). Pretreatment 
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of the arteries with eNOS antagonist attenuated the relaxation response to 
DHEA ester-enriched HDL (43% vs. 30%). Blocking of SR-BI almost 
completely abolished the relaxation response to DHEA ester-enriched HDL, 
whereas androgen and estrogen receptor blockage had no significant effect. 
In cultured endothelial cells, DHEA fatty acyl ester-enriched HDL caused 
a rapid phosphorylation of eNOS, which was ninefold compared to the effect 
of the buffer and did not differ from the effect of native HDL. When the cells 
were treated with [3H]DHEA fatty acyl ester-enriched HDL, intracellular 
radioactivity increased constantly during 24 h. The inhibition of SR-BI 
reduced this uptake by 30%. The proportion of unesterified [3H]DHEA 
increased intracellularly and in the culture media after several hours of 
treatment with [3H]DHEA ester-enriched HDL. 
Steroid sulfatase activity was higher in postmenopausal than in 
premenopausal women in abdominal subcutaneous (median 379 vs. 257 
pmol DHEAS converted to DHEA/kg tissue/h) and visceral (545 vs. 360 
pmol/kg/h) adipose tissue. Sulfatase activity was higher in visceral compared 
to subcutaneous fat in premenopausal and all women. The mRNA expression 
levels of three estradiol-producing enzymes in adipose tissue were higher in 
postmenopausal than in premenopausal women. The gene expression of 
steroid-converting enzymes varied between adipose tissue depots.  
Conclusions. DHEA fatty acyl ester-enriched HDL was a stronger 
vasodilator than native HDL, and this vascular relaxation was mediated by 
HDL receptor SR-BI. The esterification of DHEA was required for the 
improvement of the vasodilatory effect of HDL. Inhibition of eNOS 
significantly impaired the relaxation response to DHEA ester-enriched HDL, 
suggesting this response to be partly mediated by eNOS and nitric oxide. This 
is further supported by the finding in endothelial cells that DHEA ester-
enriched HDL caused a rapid phosphorylation of eNOS, which is known to 
activate the enzyme. These results suggest that DHEA esters, cargos of HDL, 
may improve the vasodilatory and antiatherogenic functions of HDL. 
Human endothelial cells were able to internalize and hydrolyze HDL-
associated DHEA fatty acyl esters and to further secrete the generated free 
DHEA from the cells. The cellular uptake was in part mediated by SR-BI. 
These results suggest that DHEA fatty acyl esters may act as hormone 
precursors transported to target tissues by lipoprotein particles. The cellular 
internalization and hydrolysis of DHEA esters were, however, slow processes 
and thus the liberated DHEA is presumably not responsible for the rapid 
vasodilatory effect of DHEA fatty acyl ester-enriched HDL. 
Steroid sulfatase activity in adipose tissue was higher in postmenopausal 
compared to premenopausal women, suggesting that circulating DHEAS 
could be more efficiently utilized by adipose tissue after menopause for the 
formation of biologically active sex hormones. Depot-differences in the 
steroid sulfatase activity and in the gene expression of steroid-converting 
enzymes suggest an important interplay between body fat distribution and 
steroid hormone metabolism. 
Introduction 
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1 INTRODUCTION 
Dehydroepiandrosterone (DHEA) and its sulfate ester 
dehydroepiandrosterone sulfate (DHEAS), secreted in large quantities by the 
adrenal glands, are important hormone precursors that can be converted to 
biologically active androgens and estrogens in peripheral tissues. In 
premenopausal women, the ovaries produce estrogens, but the contribution 
of peripheral tissues is significant, as well. At menopause, estrogen secretion 
by the ovaries completely ceases, and peripheral synthesis from adrenal 
precursors thus remains the only source of estrogens (Labrie 2015).  
DHEA fatty acyl esters are naturally occurring derivatives of DHEA, 
synthesized in blood and many tissues (Hochberg 1998). These derivatives 
are very lipophilic and thus almost exclusively incorporated in the 
lipoprotein particles in the circulation (Lavallée et al. 1996b). The biological 
role of lipoprotein-associated DHEA fatty acyl esters is unclear, but they may 
serve, after their cellular internalization and hydrolysis, as substrates for 
peripheral steroidogenesis (Vihma and Tikkanen 2011). DHEA and high-
density lipoprotein (HDL) both improve endothelial function (Yuhanna et al. 
2001, Simoncini et al. 2003). The role of HDL-associated DHEA fatty acyl 
esters in modulating vascular function is being explored in this thesis. 
In addition to circulating lipoproteins, DHEA may have relevance in 
another lipophilic environment — adipose tissue. Adipose tissue is a 
quantitatively important site of peripheral sex hormone biosynthesis. 
Adipose tissue expresses all the enzymes required for the formation of 
biologically active androgens and estrogens from adrenal prohormones (Li et 
al. 2015, Tchernof et al. 2015). Of these prohormones, DHEAS is the most 
abundant in the circulation and provides a large reservoir of substrate for the 
peripheral biosynthesis of active hormones. DHEAS is hydrophilic and thus 
needs an active transporter to cross cell membranes. After the transportation 
from the circulation to the adipose tissue, the first step in the formation of 
active sex hormones is the hydrolysis of DHEAS into DHEA, an action by 
steroid sulfatase. It has been shown that human adipocytes are able to 
internalize DHEAS, and subcutaneous adipose tissue as well as adipocytes 
can hydrolyze it (Dalla Valle et al. 2006). The capacity of adipose tissue to 
hydrolyze DHEAS has not been previously compared between 
premenopausal and postmenopausal women, or between subcutaneous and 
visceral adipose tissue depots. 
The role of DHEA in cardiovascular health remains controversial (Rice 
and Rees 2011). In the present doctoral thesis, we explored the role of DHEA 
in two different lipophilic environments — lipoproteins and adipose tissue. 
We investigated the possibility that lipophilic derivatives of DHEA 
incorporated in HDL particles could improve the vasodilatory capacity of 
HDL and therefore promote cardiovascular health. Furthermore, we 
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investigated hydrolysis of DHEAS as well as gene expression of estrogen-
producing enzymes in adipose tissue to elucidate the role of DHEA as a 
precursor of estrogens, which could influence vascular health especially in 
postmenopausal women. 
Review of the literature 
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2 REVIEW OF THE LITERATURE 
2.1 OVERVIEW OF DHEA SYNTHESIS AND 
METABOLISM 
DHEA and its sulfate ester DHEAS are the most abundant steroid hormones 
in the circulation. DHEA and DHEAS are secreted primarily from the zona 
reticularis of the human adrenal cortex and to a lesser extent from the 
ovarian theca cells (Miller and Auchus 2011, Fritz and Speroff 2011). The 
pathway of DHEA synthesis from cholesterol is shown in Figure 1. Most of 
cholesterol supply in the adrenals comes from circulating low-density 
lipoproteins (LDL) by receptor-mediated endocytosis (Carr et al. 1980, 
Gwynne and Strauss 1982, Liu et al. 2000). To initiate steroidogenesis, 
cholesterol is mobilized from the outer to the inner mitochondrial membrane 
by the steroidogenic acute regulatory protein (StAR) (Clark et al. 1994) with 
the support of other outer mitochondrial membrane proteins, including 
translocator protein (TSPO) (Papadopoulos and Miller 2012). In the inner 
mitochondrial membrane, the cholesterol side-chain cleavage enzyme 
converts cholesterol to pregnenolone (Koritz and Kumar 1970, Miller and 
Auchus 2011). Pregnenolone is sequentially converted to 17-hydroxy-
pregnenolone and then to DHEA by 17α-hydroxylase and 17, 20-lyase 
activities of the microsomal CYP17A1 enzyme. Sulfotransferase (SULT) 
enzyme SULT2A1 conjugates DHEA to form DHEAS (Miller and Auchus 
2011).  
Secretion of DHEA and DHEAS by the adrenal glands increases during 
adrenarche at the age of 6–8 years. Maximal circulating concentrations of 
these prohormones are reached between the ages of 20 and 30 years, and 
thereafter the concentrations decline markedly during aging (Orentreich et 
al. 1984, Bélanger et al. 1994, Labrie et al. 1997b, Feldman et al. 2002). In 
the plasma, DHEA is predominantly bound to albumin (88%), and only a 
small proportion of DHEA is bound to sex hormone-binding globulin 
(SHBG) (8%) or exists in nonbound form (4%) (Fritz and Speroff 2011). 
DHEA and DHEAS are important hormone precursors that can be 
converted to biologically active sex steroids in peripheral tissues by the 
mechanisms of intracrinology (Labrie et al. 2005). The production of active 
androgens and estrogens from DHEA is outlined in Figure 1. DHEAS, which 
circulates in adult men and women at 1 000–100 000 times higher 
concentrations than 17β-estradiol (estradiol) and 100–5 000 times higher 
concentrations than testosterone (Labrie et al. 2011, Simpson 2003), 
provides a large reservoir of substrate for the conversion to active androgens 
and estrogens in peripheral tissues. In premenopausal women, estrogens are 
predominantly synthesized by the ovaries. After the cessation of ovarian 
estrogen synthesis at menopause, all estrogens and almost all androgens are 
 15 
 
 
Figure 1. Principal pathways of DHEA synthesis and metabolism. CYP17A1, 17α-
hydroxylase/17,20-lyase; SULT, sulfotransferase; LCAT, lecithin:cholesterol 
acyltransferase; FAE, fatty acyl ester; HSL, hormone-sensitive lipase; STS, steroid 
sulfatase; HSD, hydroxysteroid dehydrogenase; E1, estrone; E2, 17β-estradiol; E1S, 
estrone sulfate. Not all the enzymes and metabolites are presented. 
synthesized in extragonadal sites through the enzymatic conversion from 
steroid precursors, DHEA and DHEAS (Labrie 2015). In postmenopausal 
women, approximately 80% of circulating DHEA is of adrenal origin, and 
20% is secreted by the ovaries (Labrie et al. 2011).  
The conversion of steroid precursors to active sex hormones takes place in 
a large number of peripheral tissues, including adipose tissue, brain, 
mammary gland, prostate, skin, bone, and vascular endothelium and smooth 
muscle cells (Simpson 2003, Labrie et al. 2005, Tchernof et al. 2015). This 
peripheral conversion depends on the tissue-specific expression and activity 
of steroid-converting enzymes (Labrie et al. 2005, Li et al. 2015). The local 
sex steroid synthesis provides a possibility to control the formation and 
metabolism of hormones depending on the local requirements. Peripherally 
synthesized sex hormones mostly act at the site of their synthesis either in 
the same cell or tissue in a paracrine or intracrine fashion, and only a part is 
secreted to the circulation (Labrie et al. 1997a, Labrie 2015). In 
Review of the literature 
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postmenopausal women, concentrations of estrogens are higher in tissues 
than in serum (Badeau M et al. 2007, Yamatani et al. 2013, Savolainen-
Peltonen et al. 2014, Kinoshita et al. 2014, Vihma et al. 2016), and serum 
levels of estrogens may reflect their production in tissues (Simpson 2003). 
2.2 FATTY ACYL ESTERS OF DHEA AND ESTRADIOL 
Steroid fatty acyl esters are naturally occurring lipophilic derivatives of 
steroid hormones. These derivatives, characterized as steroids bound to long-
chain fatty acids by an ester bond, are synthesized in blood and several 
tissues. In the circulation, they are transported by lipoprotein particles 
(Hochberg 1998). 
2.2.1 FORMATION AND TRANSPORT IN BLOOD 
Endogenous estradiol fatty acyl esters in human plasma were first described 
by Janocko and Hochberg (1983). Thereafter, lipophilic conjugates of DHEA, 
pregnenolone, and androst-5-ene-3β,17β-diol (androstenediol) were 
identified in human plasma, and it was demonstrated that these steroids as 
well as estradiol were converted to lipophilic conjugates when incubated with 
plasma (Jones and James 1985). In blood, the enzyme responsible for the 
fatty acyl esterification of DHEA, estradiol, pregnenolone, and 
androstenediol is lecithin:cholesterol acyltransferase (LCAT) (Roy and 
Bélanger 1989, Leszczynski et al. 1989, Leszczynski and Schafer 1991, Pahuja 
and Hochberg 1995, Lavallée et al. 1996a, Höckerstedt et al. 2002, 
Höckerstedt et al. 2004), the same enzyme that esterifies cholesterol 
(Figure 2). Of these steroid hormones, pregnenolone is the one that is most 
actively esterified in plasma, followed by DHEA and androstenediol. 
Estradiol is esterified in plasma at much lower rate than the other steroids 
(Jones and James 1985, Leszczynski and Schafer 1991, Pahuja and Hochberg 
1995, Lavallée et al. 1996a). Similarly to cholesterol, DHEA, pregnenolone, 
and androstenediol are esterified in plasma at carbon 3 position, whereas 
estradiol is esterified only at carbon 17 (Leszczynski and Schafer 1991, 
Hochberg 1998, Kanji et al. 1999) (Figure 2). The fatty acid composition of 
biosynthetic and endogenous DHEA fatty acyl esters in plasma is similar to 
that of cholesteryl esters (Leszczynski and Schafer 1991, Pahuja and 
Hochberg 1995, Lavallée et al. 1996a). 
The esterification of DHEA and estradiol in blood takes place in HDL 
particles, specifically in HDL3 subfraction (Leszczynski et al. 1989, 
Leszczynski and Schafer 1991, Höckerstedt et al. 2002). The esterifying 
enzyme, LCAT, is associated with HDL particles. From these particles, DHEA 
and estradiol fatty acyl esters can be transferred to other lipoprotein 
particles, LDL and very low-density lipoprotein (VLDL) (Roy and Bélanger 
1989, Helisten et al. 2001). The transfer of estradiol esters from HDL to other 
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Figure 2. Formation of fatty acyl esters of DHEA, estradiol, and cholesterol in plasma. The 
esterification occurs on the surface of high-density lipoprotein (HDL) particles via 
the function of lecithin:cholesterol acyltransferase (LCAT). The fatty acyl esters 
formed are incorporated in the HDL particles. apoA-I, apolipoprotein A-I. 
lipoproteins is at least partly mediated by cholesteryl ester transfer protein 
(CETP) (Helisten et al. 2001), whereas the transfer of DHEA esters is CETP-
independent (Provost et al. 1997). Fatty acyl esters of DHEA and estradiol 
are very lipophilic and thus almost exclusively associated with lipoprotein 
particles in the circulation (Larner et al. 1987, Roy and Bélanger 1989, Roy 
and Bélanger 1993, Lavallée et al. 1996b, Vihma et al. 2003a). 
DHEA fatty acyl esters circulate in humans at nanomolar concentrations 
(Labrie et al. 1997b, Wang F et al. 2011), whereas estradiol ester 
concentrations are picomolar (Vihma et al. 2003b, Badeau M et al. 2007, 
Savolainen-Peltonen et al. 2014). During aging, DHEA fatty acyl ester levels 
in serum in both men and women decline markedly, although not as 
dramatically as DHEA and DHEAS concentrations (Bélanger et al. 1994, 
Labrie et al. 1997b). In the circulation, a significant proportion of DHEA is in 
fatty acylated form. In earlier studies with immunoassay-based analytical 
methods for hormone quantification, the concentration of DHEA fatty acyl 
esters in male and female serum has been approximately half that of 
unconjugated DHEA (Roy and Bélanger 1993, Bélanger et al. 1994, Labrie et 
al. 1997b). More recently, analyzed with mass spectrometric method from 
female serum, the mean proportion of DHEA fatty acyl esters of total DHEA 
was 9% in premenopausal and 11% in postmenopausal women (Wang F et al. 
2011). 
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2.2.2 PHYSIOLOGICAL ROLE OF STEROID FATTY ACYL ESTERS 
The biological role of steroid fatty acyl esters remains still somewhat unclear. 
Lipoprotein-associated steroid fatty acyl esters, after internalization to target 
cells, may play a role in peripheral steroidogenesis. Pregnenolone fatty acyl 
esters in lipoprotein particles are internalized by porcine ovarian granulosa 
cells and hydrolyzed to pregnenolone, which is further converted to 
progesterone and other metabolites (Roy and Bélanger 1991, Roy and 
Bélanger 1992). Similarly, bovine and guinea pig adrenocortical cells can 
internalize and convert lipoprotein-associated pregnenolone fatty acyl esters 
to unconjugated steroids (Provencher et al. 1992). LDL-associated DHEA 
fatty acyl esters are internalized by ZR-75-1 human breast cancer cells and 
further converted to DHEA and androstenediol (Roy and Bélanger 1993). 
Wang F. and co-workers (2008) showed in cultured human HeLa cells that 
cellular uptake of LDL-associated DHEA fatty acyl esters was mediated by 
LDL receptors or LDL receptor-related receptors, and after the 
internalization, DHEA esters were hydrolyzed and metabolized, followed by 
the secretion of the metabolites from the cells. These studies suggest that 
lipoprotein-associated fatty acyl esters of hormone precursors may be 
transferred to peripheral cells where they can serve as substrates for the 
biosynthesis of active hormones. 
In addition to DHEA and pregnenolone, lipoprotein-associated estradiol 
may be internalized by target cells. Gong and co-workers (2003) 
demonstrated that endothelial cells were able to internalize HDL-associated 
estradiol via scavenger receptor class B, type I (SR-BI), and that HDL-
associated estradiol stimulated endothelial nitric oxide synthase (eNOS). 
Another study showed that osteoblastic cells were able to internalize 
radiolabeled estradiol associated with LDL and HDL3 particles through SR-B 
receptors (Brodeur et al. 2008). These two studies, however, did not 
characterize the molecular form of the lipoprotein-bound estradiol, and the 
authors did not discuss the possibility that estradiol could be in fatty acyl 
esterified form (Badeau M et al. 2008). Rat hepatoma cells have been 
demonstrated to rapidly internalize HDL-incorporated estradiol fatty acyl 
esters. Both SR-BI and LDL receptors were involved in this cellular uptake. 
Furthermore, the proportion of esterified estradiol decreased and that of free 
estradiol increased intracellularly during a 24-h incubation, indicating that 
estradiol esters were hydrolyzed in the cells to biologically active estradiol 
(Badeau RM et al. 2007). 
Steroid fatty acyl esters may represent a storage form of hormones. In 
adipose tissue, the concentration of estradiol fatty acyl esters is higher than 
that in serum (Larner et al. 1992, Badeau M et al. 2007, Wang F et al. 2013, 
Savolainen-Peltonen et al. 2014). Adipose tissue has a high capacity to fatty 
acyl esterify estradiol (Kanji et al. 1999, Wang F et al. 2012). De-esterifying 
enzymatic activity is present, as well (Wang F et al. 2012). As fatty acyl 
esterified estradiol is inactive and unable to bind to estrogen receptors 
(Janocko et al. 1984), the balance between the esterifying and hydrolyzing 
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capacities may play an important role in the activating and inactivating 
processes of estradiol in tissues. 
Lipoprotein-incorporated estradiol fatty acyl esters have been proposed to 
protect lipoproteins against oxidation (Shwaery et al. 1997, Shwaery et al. 
1998) and therefore to have antiatherogenic potential. In vitro, esterified 
estradiol in lipoproteins can, however, increase the resistance of lipoproteins 
against oxidation only at high supraphysiological concentrations (Meng et al. 
1999, Höckerstedt et al. 2004). Clinical studies on the effect of estrogen 
therapy against LDL oxidation have produced conflicting results and have 
not been able to confirm the antioxidative protection by estrogens (Vihma 
and Tikkanen 2011). 
2.3 EFFECTS OF DHEA AND ESTRADIOL ON THE 
CARDIOVASCULAR SYSTEM 
2.3.1 EPIDEMIOLOGY 
The dramatic age-related decline in circulating DHEA and DHEAS levels has 
been proposed to be related with the development of several diseases 
associated with aging, including cardiovascular diseases (Tchernof and 
Labrie 2004). Studies addressing the association between DHEA and 
cardiovascular diseases have produced somewhat inconsistent findings 
(Tchernof and Labrie 2004, Savineau et al. 2013, Ohlsson et al. 2015). 
Several epidemiological studies indicate that low circulating DHEA and 
DHEAS levels are associated with increased risk for cardiovascular disease 
outcomes in men (Barrett-Connor et al. 1986, Trivedi and Khaw 2001, 
Ohlsson et al. 2010, Tivesten et al. 2014), but some studies have found no 
association (Tilvis et al. 1999, Haring et al. 2013). Although the literature is 
inconsistent, available evidence suggests an association between low DHEA 
or DHEAS concentration and increased all-cause and cardiovascular 
mortality in men (Ohlsson et al. 2015), whereas in women there may be a U-
shaped association or no association (Tchernof and Labrie 2004, Ohlsson et 
al. 2015). 
The lower incidence of cardiovascular disease in premenopausal women 
compared to age-matched men and the increased risk for cardiovascular 
outcomes after the menopause have led to the suggestion that 
premenopausal women are protected from cardiovascular disease by 
endogenous estrogens (Vitale et al. 2009). Cardiovascular effects of 
postmenopausal hormone therapy are, however, controversial (Hale and 
Shufelt 2015). Several observational studies indicate a protective role of 
postmenopausal hormone therapy against coronary heart disease (Grodstein 
et al. 1999, Grodstein et al. 2000, Kim et al. 2006). Randomized placebo-
controlled trials, however, have failed to confirm cardiovascular protection 
by hormone therapy (Hulley et al. 1998, Rossouw et al. 2002). Age or time 
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since menopause at the initiation of hormone therapy may be important 
factors for modulating the cardiovascular effects. The evidence is supporting 
a beneficial effect of hormone therapy on cardiovascular health when started 
early after menopause (Mikkola and Clarkson 2002, Tuomikoski and 
Mikkola 2014). 
2.3.2 EFFECTS OF DHEA ON THE VASCULAR WALL 
Endothelial dysfunction, characterized as decreased bioavailability of nitric 
oxide, is associated with the development of cardiovascular diseases 
(Cockcroft 2005). Nitric oxide, synthesized in the vascular wall by eNOS, is a 
powerful vasodilatory, anti-inflammatory, and antiatherogenic agent 
(Landmesser et al. 2004). There is evidence that steroid hormones regulate 
vascular function. In addition to genomic effects, sex steroids have rapid, 
nongenomic actions on the vascular endothelium (Chow et al. 2010). 
Although DHEA mostly serves as a substrate for the synthesis of 
biologically active sex hormones, it also directly acts on the vascular 
endothelium. In cultured human endothelial cells, DHEA increases the 
synthesis of nitric oxide by transcriptional induction of eNOS expression as 
well as through rapid, nongenomic activation of eNOS (Simoncini et al. 
2003). These effects of DHEA are not mediated through conversion to 
androgens or estrogens (Simoncini et al. 2003). Two other studies have 
demonstrated that the rapid activation of eNOS and increased synthesis of 
nitric oxide by DHEA are mediated through a specific G-protein-coupled 
plasma membrane receptor (Liu and Dillon 2002, Liu and Dillon 2004). The 
possible membrane receptor, however, remains unidentified (Simoncini and 
Genazzani 2007). Exact cellular mechanisms by which DHEA rapidly 
activates eNOS are not fully understood. Signaling through mitogen-
activated protein kinase (MAPK) or phosphatidylinositol-3-kinase/Akt 
kinase pathways has been suggested (Simoncini et al. 2003, Liu and Dillon 
2004, Formoso et al. 2006, Bhuiyan et al. 2011).  
In ovariectomized rats, DHEA treatment has been shown to increase the 
phosphorylation of eNOS and to improve endothelium-dependent 
vasodilation in aortas isolated after the treatment (Camporez et al. 2011). In 
ovariectomized rabbits with high-cholesterol diet, DHEA treatment 
enhanced endothelium-dependent vasodilation and nitric oxide release in 
isolated aortas, and these effects were attenuated by a simultaneous 
treatment with aromatase inhibitor, suggesting that the effects of DHEA 
were partly mediated through conversion to estrogens (Hayashi et al. 2000). 
Human studies in vivo have shown that serum DHEAS concentration 
correlates positively with flow-mediated dilation of brachial artery (Akishita 
et al. 2008) and negatively with carotid intima-media thickness (Meyer et al. 
2005, Yoshida et al. 2010, Mieczkowska et al. 2012), a surrogate measure of 
atherosclerosis. Only few clinical trials of DHEA therapy on vascular function 
have been conducted in humans. In a placebo-controlled study in 24 
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hypercholesterolemic men, a short-term (12 weeks) DHEA supplementation 
improved endothelium-dependent flow-mediated dilation of the brachial 
artery, thus improving endothelial function (Kawano et al. 2003). Similarly, 
in 36 postmenopausal women, DHEA treatment increased flow-mediated 
dilation of the brachial artery and reduced serum total cholesterol 
concentrations compared to the placebo group (Williams et al. 2004). 
However, a study in 40 patients with adrenal insufficiency failed to show any 
effect of 12-week DHEA treatment on endothelial function (Rice et al. 2009). 
Furthermore, in a small study in 16 postmenopausal women, a four-week 
DHEA supplementation failed to improve flow-mediated dilation, whereas 
hormone therapy (estrogen and progestin) improved endothelial function 
(Silvestri et al. 2005). 
In addition to stimulating the nitric oxide synthesis and vasodilation, 
DHEA may improve vascular function through other mechanisms. In vitro, 
DHEA stimulates endothelial proliferation and angiogenesis (Liu et al. 
2008), protects endothelial cells against apoptosis (Liu et al. 2007), and 
regulates the synthesis of vasoconstrictor endothelin-1 (Chen et al. 2008). 
2.3.3 EFFECTS OF ESTRADIOL ON THE VASCULAR WALL 
There is a large body of evidence that estrogens regulate vascular function 
(Mendelsohn and Karas 1999, Simoncini et al. 2006, Chakrabarti et al. 
2014). Estradiol rapidly causes vasodilation in coronary and peripheral 
arteries (Williams et al. 1992, Gilligan et al. 1994, Guetta et al. 1997). In 
endothelial cells, estradiol increases eNOS expression (Kleinert et al. 1998), 
and also rapidly activates eNOS (Lantin-Hermoso et al. 1997, Chen et al. 
1999), thus stimulating the synthesis of nitric oxide (Chambliss and Shaul 
2002). The rapid, nongenomic effects of estradiol on the endothelium are 
mediated through membrane-bound estrogen receptors (Chen et al. 1999, 
Simoncini et al. 2000). Classically estrogens act through nuclear estrogen 
receptors regulating gene expression. Estrogen receptors, however, also 
function outside the nucleus, and ligand binding to these cell membrane 
receptors launches several intracellular signal cascades (Kim et al. 2008, 
Banerjee et al. 2014). On endothelial cell plasma membrane, estrogen 
receptor α and eNOS are both located in caveolae, domains enriched with 
cholesterol and sphingomyelin (Chambliss et al. 2000). In endothelial cells, 
estradiol treatment enhances, via estrogen receptor, the eNOS 
phosphorylation, which activates the enzyme leading to the secretion of nitric 
oxide (Chen et al. 1999, Wyckoff et al. 2001, Florian et al. 2004). 
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2.4 HIGH-DENSITY LIPOPROTEIN 
2.4.1 GENERAL 
The biogenesis of HDL starts with the secretion of apolipoprotein A-I 
(apoA-I) by the liver and the intestine. Secreted apoA-I acquires 
phospholipids and a small amount of cholesterol through interaction with 
ATP-binding cassette transporter A1 (ABCA1) resulting in the formation of 
nascent preβ-HDL particles. They are converted to discoidal HDL when 
acquiring additional cholesterol and phospholipids from peripheral cells. 
Discoidal HDL particles are gradually transformed into spherical particles 
via the LCAT function whereby free cholesterol is converted to cholesteryl 
esters, which form the lipophilic core of the mature HDL particle (Zannis et 
al. 2015). 
Plasma HDL particles are a heterogeneous group of particles differing in 
size, shape, charge, and composition. HDL particles transport lipids, 
proteins, vitamins, steroid hormones, different metabolites, and small RNAs. 
These numerous cargos of HDL are transported between the tissue sites and 
are important for the functionality of HDL (Vickers and Remaley 2014). 
2.4.2 ANTIATHEROGENIC FUNCTIONS OF HDL 
Low plasma HDL cholesterol concentration is a strong risk factor for 
cardiovascular disease. Epidemiological studies indicate that the HDL 
cholesterol level in blood is inversely correlated with the risk for 
cardiovascular disease (Miller and Miller 1975, Gordon et al. 1977). However, 
recent clinical trials aiming at rising HDL cholesterol have failed to reduce 
cardiovascular events (Barter et al. 2007, AIM-HIGH Investigators 2011, 
Schwartz et al. 2012). In addition to these clinical trials, studies of human 
genetics have failed to support the conventional HDL cholesterol hypothesis 
(Edmondson et al. 2009, Voight et al. 2012). These findings have led to the 
understanding of the complexity of HDL biology. The HDL-mediated 
atheroprotection may be related to the functionality of HDL, and not 
necessarily to elevated HDL cholesterol levels (Vickers and Remaley 2014, 
Kontush 2014). 
HDL particles have several atheroprotective activities, which include 
reverse cholesterol transport, vasodilatory, cytoprotective, anti-
inflammatory, antioxidative, and antithrombotic actions as well as regulating 
gene expression by microRNAs and improving glucose metabolism (Kontush 
2014). The clinical relevance and importance of these mechanisms are still 
partly unclear. The best studied and most important biological activity of 
HDL is the function in the reverse cholesterol transport process, i.e. removal 
of cholesterol from peripheral tissues and transport to the liver for excretion. 
HDL particles acquire cholesterol from arterial walls, primarily from 
macrophages and macrophage-derived foam cells. The esterified cholesterol 
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in HDL particles is taken directly to the liver and steroidogenic tissues by 
SR-BI-mediated selective uptake or transferred by CETP to VLDL and LDL 
particles, which are eventually delivered to the liver by LDL receptors. From 
the liver, cholesterol is used for bile acid synthesis or directly excreted into 
the bile (Lewis and Rader 2005). 
2.4.2.1 Vasodilatory effects of HDL 
In addition to its role in the reverse cholesterol transport process, HDL 
directly acts on the vascular endothelium, thus influencing cardiovascular 
health. On the endothelium, HDL has vasodilatory activity, which is 
primarily mediated through nitric oxide release by endothelial cells 
(Yuhanna et al. 2001, Nofer et al. 2004) but also through production of 
prostacyclin (Norata et al. 2004, Zhang et al. 2012). HDL stimulates eNOS 
activity in cultured endothelial cells and causes endothelium-dependent 
vasodilation in isolated mouse aortas (Yuhanna et al. 2001). These effects are 
mediated through HDL binding to SR-BI (Yuhanna et al. 2001, Li et al. 
2002), which is expressed in endothelium and highly enriched in caveolae 
(Uittenbogaard et al. 2000, Yuhanna et al. 2001). In addition to SR-BI, 
sphingosine-1-phosphate (S1P) receptors are involved in eNOS activation by 
HDL (Nofer et al. 2004, Kimura et al. 2006). S1P, a cargo of HDL, binds to 
apolipoprotein M in HDL and mediates vasculoprotective actions through 
S1P receptors on the endothelium (Christoffersen et al. 2011, Karuna et al. 
2011). S1P has been shown to cause vasodilation in aortic rings of mice and 
rats (Nofer et al. 2004, Roviezzo et al. 2006). In aortas from mice lacking the 
S1P3 receptor, the vasodilatory effect of HDL is partly attenuated (Nofer et al. 
2004). The induction of nitric oxide and prostacyclin by HDL-associated S1P 
are of importance in the regulation of many cellular events, including 
proliferation, apoptosis, cell adhesiveness, angiogenesis, and vascular 
integrity (Rodríguez et al. 2009). Both SR-BI and S1P receptors are involved 
in the vasculoprotective effects of HDL (Rodríguez et al. 2009, Mineo and 
Shaul 2012). 
The activity of eNOS is regulated by complex signal transduction 
pathways, involving activation of several kinases leading to changes in the 
phosphorylation state of eNOS (Mineo and Shaul 2013). HDL stimulates 
phosphorylation of Akt kinase, which in turn phosphorylates eNOS at 
serine-1177. HDL also causes parallel activation of the MAP kinase pathway, 
and these two pathways lead to the activation of the eNOS enzyme (Mineo et 
al. 2003).  
HDL enhances the production of nitric oxide and subsequent 
vasorelaxation by several other mechanisms than modulating eNOS activity. 
HDL increases the half-life of eNOS protein and thus the abundance of the 
enzyme (Rämet et al. 2003). HDL preserves, in the presence of oxidized LDL, 
the lipid environment in the caveolae, and thereby maintains the subcellular 
localization and normal function of eNOS (Uittenbogaard et al. 2000).  
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Several studies in humans have demonstrated the relationship between 
HDL cholesterol levels and endothelium-dependent vasodilation. Elevated 
serum HDL cholesterol ameliorates the abnormal endothelium-dependent 
vasodilation in coronary arteries in patients with early stage of coronary 
atherosclerosis (Zeiher et al. 1994). Furthermore, HDL cholesterol levels 
correlate positively with flow-mediated dilation of the brachial artery (Li et 
al. 2000, Kuvin et al. 2003). 
Steroid hormones, also cargos of HDL, may play a role in vasodilation 
caused by the lipoprotein. Gong and co-workers (2003) demonstrated that 
HDL delivered estradiol to endothelial cells, and HDL isolated from women 
had a significantly higher capacity in endothelial cells to activate eNOS than 
had HDL from men, suggesting that HDL-associated estradiol could mediate 
eNOS activation by HDL. Another study, however, found no difference 
between the relaxation responses to female HDL and male HDL in isolated 
mouse aortic rings (Nofer et al. 2004). In vivo in humans, change in serum 
estradiol fatty acyl ester concentration during postmenopausal estrogen 
treatment correlated positively with enhanced forearm blood flow responses 
(Vihma et al. 2003b). Steroid fatty acyl esters, such as DHEA and estradiol 
esters, are associated with HDL particles in the circulation. The possible role 
of HDL-associated DHEA and estradiol fatty acyl esters in HDL-mediated 
eNOS activation and vasodilation has not been previously studied.  
2.5 STEROID HORMONE METABOLISM IN ADIPOSE 
TISSUE 
Adipose tissue is not only an energy storage, but rather an active endocrine 
and metabolic organ that contributes to the metabolic homeostasis by 
secreting and metabolizing a large variety of adipokines and hormones 
(Kershaw and Flier 2004). Accumulation of visceral adipose tissue is 
associated with metabolic alterations that increase the risk for metabolic 
syndrome, type 2 diabetes, and cardiovascular disease (Fox et al. 2007, 
Smith et al. 2012). Sex hormones are important regulators of body fat 
distribution patterns (Tchernof and Després 2013). 
2.5.1 FORMATION OF ANDROGENS AND ESTROGENS IN ADIPOSE 
TISSUE 
Adipose tissue is an active endocrine organ and an important site for 
extragonadal steroid hormone biosynthesis and metabolism. This is 
supported by the findings that the concentrations of DHEA, 
androstenedione, estradiol, and estrone are higher in adipose tissue than in 
blood (Deslypere et al. 1985, Badeau M et al. 2007, Wang F et al. 2011, 
Savolainen-Peltonen et al. 2014, Kinoshita et al. 2014, Vihma et al. 2016). 
Adipose tissue contains all the necessary enzyme machinery for the synthesis 
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of biologically active androgens and estrogens from the adrenal steroid 
precursors, DHEA and DHEAS (Tchernof et al. 2015, Li et al. 2015) 
(Figure 1). In premenopausal women, estrogens are secreted by the ovaries, 
but the extragonadal synthesis represents a significant source, as well (Labrie 
et al. 2003). In postmenopausal women and in men, extragonadal synthesis 
is the only source of estrogens (Labrie et al. 2003, Simpson 2003, Labrie 
2015). Adipose tissue is one of the largest endocrine tissues and thus 
quantitatively important in the formation of active sex hormones. The 
concentration of DHEA in adipose tissue in women is approximately ten 
times higher than that in serum (Deslypere et al. 1985, Wang F et al. 2011, 
Kinoshita et al. 2014), suggesting that DHEA and DHEAS are effectively 
transferred from the circulation to the adipose tissue. 
It is uncertain whether adipose tissue is able to generate de novo sex 
hormones directly from cholesterol. Gene expression of StAR, a protein 
required for the delivery of cholesterol to the inner mitochondrial 
membrane, has been detected at low levels in subcutaneous and visceral 
adipose tissue obtained from pregnant women undergoing caesarean section 
(MacKenzie et al. 2008) as well as from obese male and female subjects 
(Hernandez-Morante et al. 2009). Gene expression of cholesterol side-chain 
cleavage enzyme has also been found in both adipose tissue depots 
(MacKenzie et al. 2008). The activity of this enzyme in adipose tissue is, 
however, unknown. In subcutaneous adipose tissue of women, 17α-
hydroxylase activity of CYP17A1, measured as conversion of progesterone to 
17α-hydroxyprogesterone, has been detected (Puche et al. 2002). 
Furthermore, both 17α-hydroxylase and 17, 20-lyase activities of CYP17A1 
have been found in human subcutaneous and visceral fat (Kinoshita et al. 
2014). Other studies, however, failed to detect mRNA expression of CYP17A1 
in adipose tissue (Dalla Valle et al. 2006, MacKenzie et al. 2008, Wang L et 
al. 2012). In the study by Dalla Valle and co-workers (2006), mRNA 
expression of any of these key proteins and enzymes, namely StAR, 
cholesterol side-chain cleavage enzyme, and CYP17A1, could not be detected 
in human subcutaneous adipose tissue. Thus, the ability of adipose tissue to 
synthesize active steroid hormones from cholesterol remains uncertain, 
whereas the capacity of adipose tissue acting as a major steroid-converting 
site is well established. 
2.5.2 HYDROLYSIS OF STEROID SULFATES BY STEROID 
SULFATASE 
Sulfated steroids have been considered as inactive metabolic end products 
that are water-soluble and thus secreted to the urine. However, over the past 
two decades, extensive research indicates that inactive steroid sulfates are 
important sources of active steroid hormones. DHEAS circulates at 
micromolar concentration, and thus provides a large reservoir of substrate 
for peripheral steroidogenesis. Estrone sulfate is the most abundant 
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circulating estrogen in postmenopausal women (Labrie et al. 2011). DHEAS 
and estrone sulfate have prolonged half-lives in plasma compared to 
unconjugated DHEA and estrone (Ruder et al. 1972, Kroboth et al. 1999). 
High plasma concentrations of DHEAS and estrone sulfate together with 
their long half-lives have given rise to the view that these steroid conjugates 
could act as reservoirs of substrate for the formation of active hormones 
(Reed et al. 2005, Mueller et al. 2015). Sulfation and desulfation of steroid 
hormones represent an important mechanism in regulating steroidogenesis 
and hormone action in tissues (Mueller et al. 2015).  
DHEAS and estrone sulfate are hydrophilic and thus unable to cross cell 
membranes. They require active transmembrane transport for cellular 
uptake. This uptake is performed by two organic anion carrier protein 
families: organic anion transport polypeptides (OATPs) (Hagenbuch and 
Stieger 2013) and organic anion transporters (OATs) (Koepsell 2013). These 
proteins are expressed in several tissues and possess distinct substrate 
specificity and uptake kinetics for different steroid sulfate conjugates 
(Mueller et al. 2015). Primary transporters of sulfated steroids appear to be 
the OATPs (Mueller et al. 2015), but also some OATs can transport steroid 
sulfates, as shown in human placenta (Cha et al. 2000). Dalla Valle and co-
workers (2006) found that in human subcutaneous adipose tissue, genes 
encoding three OATPs, namely OATP-B, OATP-D, and OATP-E, were 
expressed, while other members of the OATP and OAT families were not. 
Furthermore, transmembrane transport of DHEAS was observed in cultured 
preadipocytes and mature adipocytes (Dalla Valle et al. 2006). 
Once internalized, DHEAS and estrone sulfate must be hydrolyzed before 
being further converted to active steroid hormones. Steroid sulfatase, a 
membrane-bound microsomal enzyme, catalyzes desulfation of its two major 
substrates DHEAS and estrone sulfate to DHEA and estrone, respectively 
(Reed et al. 2005, Purohit et al. 2011, Mueller et al. 2015). Steroid sulfatase 
activity was first demonstrated in rat liver microsomes by Dodgson and co-
workers (1954). Since then, steroid sulfatase has been found in several 
tissues, such as adrenals, prostate, breast, ovary, testis, skin, brain, bone, 
thyroid, pancreas, and endometrium, which all show steroid sulfatase activity 
(Mueller et al. 2015). In adipose tissue, Martel and co-workers (1994) were 
the first to show significant DHEA and estrone sulfatase activity in 
mesenteric fat of rhesus monkey. In human subcutaneous adipose tissue, the 
gene and protein expression as well as activity of steroid sulfatase in the 
conversion of DHEAS to DHEA have been detected (Dalla Valle et al. 2006). 
Furthermore, preadipocytes and adipocytes are able to hydrolyze DHEAS 
(Dalla Valle et al. 2006). In human visceral adipose tissue, steroid sulfatase 
activity has not been previously studied. However, mRNA expression of 
steroid sulfatase gene (STS) has been detected both in subcutaneous and in 
visceral adipose tissue depots (Blouin et al. 2009a, Wang F et al. 2013). 
Relatively little is known about the regulation of steroid sulfatase 
expression and activity. The STS gene displays alternative promoter usage 
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and splicing, which is thought to be the basis for the tissue-specific 
regulation (Mueller et al. 2015). In adipose tissue, transcriptional regulation 
of steroid sulfatase seems to differ from that of placental steroid sulfatase 
(Dalla Valle et al. 2006). Steroid sulfatase can be controlled via 
posttranscriptional and posttranslational modifications, such as 
glycosylation (Stein et al. 1989). Breast cancer tissue displays high estrone 
sulfatase activity (Santner et al. 1984, Pasqualini et al. 1996), and the mRNA 
expression levels of STS are higher in cancer compared to normal tissue 
(Utsumi et al. 2000, Honma et al. 2006), suggesting an important role of 
steroid sulfatase in hormone-dependent tumor growth (Purohit and Foster 
2012). The exact mechanisms stimulating steroid sulfatase expression and 
activity in breast cancer are somewhat unclear. In breast cancer cells, STS 
mRNA expression is upregulated by estradiol (Evans et al. 1993, Zaichuk et 
al. 2007). Inflammatory cytokines, such as tumor necrosis factor α (TNFα), 
interleukin-6 (IL-6), and IL-1β, increase estrone sulfatase activity in breast 
cancer cells (Purohit et al. 1996, Newman et al. 2000, Honma et al. 2002). 
The enhanced activity of steroid sulfatase by IL-6 and TNFα was observed 
without an increase in STS mRNA expression, suggesting a posttranslational 
effect (Newman et al. 2000). In hepatic cells, inflammatory stimuli induce 
gene expression and activity of steroid sulfatase, thus activating estrogens, 
which in return attenuate the inflammation via the estrogen receptor 
signaling (Jiang et al. 2016). In adipose tissue, the regulation of steroid 
sulfatase activity is largely unknown. 
2.5.3 OTHER STEROID-METABOLIZING ENZYMES 
DHEA, derived from the circulation or from desulfation of DHEAS in the 
peripheral tissue, can be further converted to active sex steroids by 
sequential action of steroid-converting enzymes. The classical pathway of the 
production of androgens and estrogens from DHEA is shown in Figure 1. In 
addition to this classical pathway, there may be other enzymes and pathways 
involved in steroid biosynthesis in peripheral tissues. These alternative 
pathways may have relevance in peripheral steroidogenesis and especially in 
the local production of active sex steroids in cancerous tissues, such as 
prostate cancer (Fokidis et al. 2015). 
In adipose tissue and adipocytes, DHEA can be reduced to androstenediol 
(Schindler and Aymar 1975, Marwah et al. 2006) in a reaction catalyzed by 
17β-hydroxysteroid dehydrogenase (17βHSD) enzymes (Tchernof et al. 
2015). Androstenediol, although structurally an androgen, binds to estrogen 
receptors (Kuiper et al. 1997) and has estrogenic properties, such as 
stimulation of breast cancer cell proliferation in an estrogen receptor-
dependent manner (Poulin and Labrie 1986, Purohit et al. 2011). In cultured 
stromal cells from breast adipose tissue, DHEA is converted to 
androstenedione and estrone, indicating 3βHSD and aromatase activities 
(Killinger et al. 1995). Aromatase activity, in the conversion of 
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androstenedione to estrone (Nimrod and Ryan 1975, Forney et al. 1981, 
Deslypere et al. 1985) and testosterone to estradiol (Nimrod and Ryan 1975, 
Forney et al. 1981), has been demonstrated in adipose tissue.  
Estrone can be reduced to biologically active estradiol by 17βHSDs in 
adipose tissue (Martel et al. 1992) and adipocytes (Bellemare et al. 2009). Of 
the enzyme isoforms of 17βHSD, types 1, 7, and 12 are known to convert 
estrone to estradiol  (Saloniemi et al. 2012, Tchernof et al. 2015). It is 
unclear, however, which of these isoenzymes are responsible for the 
conversion of estrone to estradiol in adipose tissue. In human adipocytes, the 
mRNA expression of type 12 was higher compared to types 1 and 7, 
suggesting that 17βHSD type 12 may act as one of the enzymes converting 
estrone to estradiol in adipose tissue (Bellemare et al. 2009, Tchernof et al. 
2015). Based on studies in genetically modified mouse models, 17βHSD 
enzymes have, in addition to their role in sex steroid metabolism, important 
roles in other metabolic processes (Saloniemi et al. 2012). Type 7 isoform of 
17βHSD is essential for cholesterol biosynthesis in mice, and type 12 is 
involved in the elongation of essential fatty acids, such as arachidonic acid, 
thus influencing prostaglandin synthesis. 
In adipocytes derived from adipose tissue of men (Blouin et al. 2006) and 
women (Blouin et al. 2003, Blouin et al. 2009a), androstenedione was 
reduced to testosterone by 17βHSD activity and also to a more potent 
androgen, dihydrotestosterone, indicating the presence of 5α-reductase 
activity. In addition to the classical pathway proceeding through DHEA and 
testosterone, dihydrotestosterone is proposed to be synthesized by an 
alternative pathway, also called “backdoor” pathway, in which 
dihydrotestosterone is produced from an inactive steroid, 3α-androstanediol 
(Auchus 2004, Luu-The 2013). The existence of this pathway has not been 
described in adipose tissue. 
Hormone-sensitive lipase, an enzyme participating in the hydrolysis of 
triacylglycerols in adipose tissue (Holm 2003), is able to hydrolyze fatty acyl 
esters of DHEA and is partly responsible for the hydrolysis of estradiol fatty 
acyl esters in adipose tissue (Wang F et al. 2012). In adipose tissue in 
women, a significant proportion of estradiol is in inactive fatty acyl esterified 
form (Larner et al. 1992, Badeau M et al. 2007, Wang F et al. 2013, 
Savolainen-Peltonen et al. 2014), whereas DHEA fatty acyl esters have not 
been detected (Wang F et al. 2011). DHEA esters are more efficiently 
hydrolyzed compared to estradiol esters in adipose tissue in vitro (Wang F et 
al. 2012). 
2.5.4 DIFFERENCES IN STEROID HORMONE METABOLISM 
BETWEEN SUBCUTANEOUS AND VISCERAL ADIPOSE TISSUE 
Sex steroids are important regulators of adiposity and body fat distribution. 
Body fat distribution differs between men and women. Men and 
postmenopausal women usually have increased visceral adiposity, whereas 
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premenopausal women tend to have increased subcutaneous fat 
accumulation (Tchernof and Després 2013, Palmer and Clegg 2015). 
Estrogen receptors α and β are present in adipose tissue, supporting the 
direct estrogenic action in adipose tissue (Mizutani et al. 1994, Crandall et al. 
1998, Dieudonné et al. 2004). Reduced estrogen levels in postmenopausal 
women have been associated with increased visceral fat accumulation after 
menopause (Genazzani and Gambacciani 2006, Lovejoy et al. 2008). 
Steroid hormone metabolism appears to be somewhat different between 
adipose tissue depots. In obese men, androgen concentrations differ between 
abdominal subcutaneous and visceral adipose tissues and associate positively 
with lipolytic responsiveness in omental adipocytes suggesting a regulatory 
effect of androgens in this depot (Bélanger et al. 2006). Several steroid-
converting enzyme genes display different expression levels in subcutaneous 
and visceral adipose tissue depots. Steroid sulfatase gene is more expressed 
in subcutaneous than in visceral adipose tissue in women (Blouin et al. 
2009a, Wang F et al. 2013) and in obese men (Wang F et al. 2013). In 
preadipocytes derived from female omental adipose tissue, the STS mRNA 
expression was higher than in preadipocytes from subcutaneous fat, and 
following adipocyte differentiation, the STS expression increased (Blouin et 
al. 2009a). These findings suggest that the differences in the STS expression 
between adipose tissue depots may be due to the relative proportion of 
mature adipocytes and preadipocytes in each depot (Blouin et al. 2009a). In 
addition to steroid sulfatase, the mRNA expression levels of aromatase and 
hormone-sensitive lipase seem to be higher in subcutaneous than in visceral 
adipose tissue (Reynisdottir et al. 1997, Blouin et al. 2006, Ray et al. 2009, 
Wang F et al. 2013). Other studies, however, have reported no difference in 
the mRNA expression of hormone-sensitive lipase between adipose tissue 
depots (Montague et al. 1998, Lefebvre et al. 1998). 
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3 AIMS OF THE STUDY 
DHEA and DHEAS are important prohormones. Their metabolism in 
adipose tissue is of particular interest, since adipose tissue is a major source 
of biologically active estrogens and androgens in postmenopausal women. In 
addition to adipose tissue, DHEA may have physiological relevance in 
another lipophilic environment, i.e., circulating lipoproteins. DHEA fatty acyl 
esters, naturally occurring lipophilic derivatives of DHEA, are carried in 
lipoprotein particles in the circulation. Both DHEA and HDL are vascular 
relaxants. However, the vasodilatory capacity of DHEA fatty acyl esters 
incorporated in HDL particles has not been previously studied. 
 
The aims of the present study were: 
 
1. To study the fatty acyl esterification of DHEA in human plasma and 
the association of DHEA fatty acyl esters with human plasma 
lipoproteins (I) 
2. To investigate in isolated rings of rat mesenteric arteries whether 
HDL-associated DHEA fatty acyl esters improve the vasodilatory 
capacity of HDL, and to study the role of eNOS, HDL receptor SR-BI 
as well as androgen and estrogen receptors in the arterial responses (I 
and II) 
3. To study the possible internalization and hydrolysis of HDL-
associated DHEA fatty acyl esters in human endothelial cells (II) 
4. To study the activity of steroid sulfatase, determined as the conversion 
of DHEAS to DHEA, and to quantify the expression levels of steroid-
converting enzyme genes in abdominal subcutaneous and visceral 
adipose tissue from pre- and postmenopausal women (III) 
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4 MATERIALS AND METHODS 
4.1 SUBJECTS AND SAMPLES 
The study protocols were approved by the ethics committee of Helsinki 
University Central Hospital, and written informed consent was obtained 
from the subjects. 
4.1.1 BLOOD SAMPLES FOR INCUBATIONS OF STEROIDS WITH 
PLASMA 
Blood samples were obtained from healthy, normolipidemic male and female 
donors to study the incorporation of radiolabeled DHEA in lipoproteins. 
Plasma was prepared by immediate centrifugation at 1730 × g, 10 min, 
+10 °C and used for experiments during the same day (I). 
For the arterial relaxation studies, blood was drawn from one healthy, 
normolipidemic, premenopausal woman (44 years of age, normal weight, no 
medication). Plasma was isolated by centrifugation and used for experiments 
during the same day (I, II). 
To examine the internalization and hydrolysis of HDL-associated DHEA 
fatty acyl esters in cultured endothelial cells, blood was drawn from five 
healthy, normolipidemic (mean total cholesterol 4.60 mmol/l and 
triglycerides 1.36 mmol/l) premenopausal women receiving no hormonal 
medication. Plasma was isolated, pooled, and stored at −80 °C for further 
experiments (II). 
To study the phosphorylation of eNOS in cultured endothelial cells, blood 
samples were taken from five healthy, normolipidemic (mean total 
cholesterol 4.48 mmol/l and triglycerides 0.98 mmol/l) premenopausal 
women receiving no hormonal medication. Plasma was isolated, pooled, and 
stored at −80 °C for further experiments (unpublished). 
4.1.2 UMBILICAL CORDS FOR ENDOTHELIAL CELL CULTURES 
Umbilical cords were obtained after deliveries of term (gestational week 
37−42) pregnancies of healthy, nonsmoking women. Endothelial cells were 
isolated from umbilical veins, cultured, and used freshly for experiments 
(unpublished). 
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4.1.3 BLOOD AND ADIPOSE TISSUE SAMPLES FOR ENZYME 
ACTIVITY, mRNA EXPRESSION, AND HORMONE ASSAYS 
In Study III, blood and adipose tissue samples were obtained from 18 
premenopausal and seven postmenopausal women undergoing elective 
gynecological surgery for non-malignant reasons. None of the women 
received systemic estrogen or progestin treatment. Clinical characteristics of 
the study subjects are shown in Table 1. Blood samples were drawn before 
the operation. Serum was isolated by centrifugation and stored at −20 °C 
until the analyses. During the operation, paired abdominal subcutaneous and 
visceral adipose tissue samples were taken and snap-frozen in liquid 
nitrogen. The tissue samples were stored at −80 °C until further processing. 
Table 1. Clinical characteristics of the patients in Study III. 
 Premenopausal Postmenopausal  
 n=18 n=7 P valuea 
Age (years) 43.9 (29.3−51.9) 56.0 (52.3−74.8) <0.001 
Body mass index, (kg/m2) 28 (21−35) 25 (22−34) 0.615 
Waist-to-hip ratio 0.85 (0.73−0.99) 0.90 (0.82−1.05) 0.130 
Serum FSH (IU/l)b 7 (1−18) 70 (26−188) <0.001 
Serum SHBG (nmol/l) 61 (31−96) 60 (24−97) 0.929 
The data are expressed as median (range). 
aComparison premenopausal vs. postmenopausal (Mann-Whitney U Test). 
bReference value for postmenopausal women 26−135 IU/l. 
FSH, follicle-stimulating hormone; SHBG, sex hormone-binding globulin. 
4.2 METHODS 
4.2.1 INCUBATION OF STEROIDS WITH PLASMA  
4.2.1.1 Incorporation of DHEA in lipoproteins (Study I) 
Radiolabeled DHEA ([1,2,6,7-3H(N)]DHEA) was added in 0.5 mol/l HEPES 
buffer (pH 7.4) (ethanol/HEPES 1:4, v/v) to freshly isolated plasma to reach 
a final concentration of 53 nmol/l (7 × 106 dpm/ml). The incubation was 
performed at +37 °C for 4 h in the presence and absence of LCAT inhibitor 
dithionitrobenzoic acid (DTNB; 1.5 mmol/l, final concentration). 
 33 
4.2.1.2 Plasma incubation for cell culture experiments (Study II) 
To prepare [3H]DHEA fatty acyl ester-enriched HDL, [3H]DHEA in ethanol 
was added to thawed plasma to reach a final concentration of 212 nmol/l 
(4.44 × 107 dpm/ml), and the mixture was incubated at +37 °C for 21 h. 
4.2.1.3 Plasma incubation for arterial relaxation study (Studies I and II) 
To prepare steroid fatty acyl ester-enriched HDL, DHEA or estradiol was 
dissolved in ethanol, diluted with HEPES (ethanol/HEPES 1:4, v/v) and 
added to freshly isolated plasma to reach a final concentration of 10 μmol/l. 
The mixture was incubated at +37 °C for 4 h. Plasma incubation with the 
vehicle (ethanol/HEPES) served as the control. Incubation of DHEA with 
plasma was also performed in the presence of LCAT inhibitor DTNB 
(1.5 mmol/l). 
4.2.1.4 Plasma incubation for endothelial nitric oxide synthase assay 
(unpublished) 
To prepare DHEA fatty acyl ester-enriched HDL, DHEA (Sigma, St. Louis, 
MO, USA) was dissolved in ethanol, diluted with HEPES buffer 
(ethanol/HEPES 1:4, v/v) and added to thawed, pooled female plasma to 
reach a final concentration of 10 μmol/l, and the mixture was incubated at 
+37 °C for 21 h. Incubation of the vehicle with plasma served as control. 
4.2.2 ISOLATION AND PURIFICATION OF LIPOPROTEINS 
After the incubations, lipoproteins were isolated from plasma by sequential 
ultracentrifugation (Havel et al. 1955). The density ranges were as follows: 
VLDL, <1.006 g/ml; LDL, 1.006–1.063 g/ml; HDL, 1.063–1.21 g/ml. 
Ultracentrifugally isolated lipoproteins were further purified from weakly 
associated small-molecular-weight substances by size-exclusion 
chromatography on Sephadex G25 column (column dimension 1 cm × 
20 cm). Phosphate-buffered saline (PBS; pH 7.4) was used as elution buffer. 
Protein concentration in the purified lipoprotein fractions was determined by 
the method of Lowry et al. (1951). Following purification of lipoproteins 
containing [3H]-label, radioactivity was determined by liquid scintillation 
counting. 
4.2.3 THIN-LAYER CHROMATOGRAPHY 
The radioactivity associated with HDL and LDL was further analyzed by 
thin-layer chromatography (TLC) in Studies I and II. The purified HDL or 
LDL fraction was extracted four times with ethyl acetate/diethyl ether (1:1, 
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v/v) (3 × sample volume). The organic phase was evaporated, and the 
extracted lipids were dissolved in methanol and applied to TLC plate 
(20 cm × 20 cm, Silica gel 60). In Study I, part of the extracted sample was 
saponified in order to hydrolyze the DHEA fatty acyl esters formed. After 
saponification in methanolic potassium hydroxide at +60 °C for 2 h, the 
samples were neutralized with distilled water and HCl, extracted twice with 
diethyl ether, and applied to TLC. 
Nonradioactive DHEA and DHEA-3-oleate served as standards. DHEA-3-
oleate was synthesized as described in Study I. Hexane/ethyl acetate (7:3, v/v 
or 1:1, v/v) was used to develop the TLC plate. The locations of the standards 
were visualized under UV light after rhodamine staining. The locations of the 
samples containing 3H-label were determined by dividing the lane into 1-cm 
strips, which were scraped and used for radioactivity measurement. 
4.2.4 ARTERIAL RESPONSES IN VITRO (STUDIES I AND II) 
Relaxation responses to DHEA, estradiol, and different HDLs were studied in 
isolated rings of rat mesenteric arteries. The mesenteric arteries of male 
Wistar rats were excised, and endothelium-intact sections (2−3 mm) of 
arteries were placed between stainless-steel hooks in an organ bath chamber 
in physiological salt solution. The force of contraction was measured with an 
isometric force-displacement transducer. Arterial rings were equilibrated for 
60 min with the resting tension of 1.5 g, followed by precontraction with 
1 μmol/l noradrenaline. The relaxation responses were observed after adding 
increasing doses of the following components at 6-min intervals: (a) DHEA 
in ethanol; (b) estradiol in ethanol; (c) HDL isolated after the incubation of 
DHEA with plasma; (d) HDL from the incubation of DHEA with plasma in 
the presence of LCAT inhibitor DTNB; (e) HDL from the incubation of 
estradiol with plasma; (f) native HDL from the plasma incubation with the 
vehicle (ethanol/HEPES). In selected experiments, the rings were pretreated 
with the NOS antagonist nitro-L-arginine methyl ester (L-NAME; 
0.1 mmol/l, final concentration). In other experiments, the function of HDL 
receptor SR-BI was attenuated by pretreatment of the arterial rings with 
thiosemicarbazone BLT-1 (blocker of lipid transport; 1 μmol/l). Furthermore, 
selected experiments were performed after pretreatment of the rings with 
estrogen receptor α and β antagonist ICI 182,780 (1 μmol/l) or androgen 
receptor antagonist bicalutamide (1 μmol/l).  
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4.2.5 ENDOTHELIAL NITRIC OXIDE SYNTHASE ASSAY 
(UNPUBLISHED) 
4.2.5.1 Cell culture 
Human umbilical vein endothelial cells (HUVEC) were isolated from freshly 
obtained human umbilical cord veins as described by Jaffe et al. (1973) with 
some modifications (Ristimäki et al. 1991, Mikkola et al. 1993). Briefly, the 
cord veins were cannulated and washed three times with 20 ml of phosphate-
buffered saline (PBS, pH 7.4; Lonza, Verviers, Belgium), after which the cells 
were digested with 0.3 g/l collagenase type IV (Sigma-Aldrich, St. Louis, MO, 
USA) in PBS for 10 min at +37 °C. After collecting the collagenase, the cord 
veins were washed with medium (Media 199, Life Technologies, Paisley, UK) 
supplemented with 2 mmol/l L-glutamine (Life Technologies) and 50 mg/l 
gentamicin (Life Technologies), and the wash medium was added to the 
collagenase. The cells were then collected by centrifugation (107 × g, 8 min) 
and resuspended in 5 ml culture medium containing Media 199 
supplemented with 2 mmol/l L-glutamine, 50 mg/l gentamicin, 10% fetal 
bovine serum (HyClone Laboratories, Logan, UT, USA), 3.8 kU/l heparin 
(Sigma-Aldrich), and 25 mg/l Endothelial Cell Growth Supplement (ECGS; 
BD Biosciences, Bedford, MA, USA). The cells and the medium were 
transferred into cell culture flasks, and after maintaining the culture for 2 h 
at +37 °C, the medium was changed. Thereafter, the medium was changed 
every second or third day. Confluent cultures were detached with 0.05% 
Trypsin-EDTA (Life Technologies) and passed at a split ratio of 1:3. The last 
seeding for the experiment was performed in 75-cm2 flasks in the passage 
2−4. Before the experiment, the cells were first preincubated in the culture 
medium containing phenol red-free Minimum Essential Medium (MEM; Life 
Technologies), 10% Charcoal/Dextran Treated Fetal Bovine Serum (DCC-
FBS; HyClone Laboratories), L-glutamine, and gentamicin for 24 h, and then 
for additional 12 h in similar medium containing only 2% DCC-FBS. The 
experimental medium was phenol red-free MEM supplemented with 0.1% 
BSA (Sigma-Aldrich), L-glutamine, and gentamicin. All culture flasks were 
pretreated with 0.2% gelatin (Merck Millipore, Billerica, MA, USA) for 
30 min at +37 °C. 
4.2.5.2 Experimental design 
DHEA fatty acyl ester-enriched HDL (DHEA ester-enriched HDL) and native 
HDL were prepared as described in the sections 4.2.1.4 and 4.2.2. HUVECs 
were treated with DHEA ester-enriched HDL, native HDL, or PBS (vehicle 
control) for 5, 10, 60, and 180 min. The final HDL protein concentration in 
the experiment medium was 100 μg/ml. To study the effect of unesterified 
DHEA without HDL, DHEA (100 nmol/l, final concentration) in ethanol was 
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added to HUVEC culture and incubated for 60 min. Incubation with ethanol 
(0.02%, v/v) served as control. After the incubations, the media were 
removed, and the cells were washed twice with PBS and lysed with RIPA 
buffer (Sigma-Aldrich) containing protease inhibitor cocktail (Sigma-
Aldrich). In every experiment, one flask of cells was lysed before any 
treatment at the baseline. The cell lysates were stored at −140 °C. Total 
protein concentrations of the cell lysates were determined by Pierce BCA 
Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). 
4.2.5.3 Western blot analysis 
Western blot analysis was carried out to examine protein levels of eNOS and 
serine-1177-phosphorylated eNOS in HUVECs after the treatment with 
DHEA ester-enriched HDL, native HDL, PBS control, DHEA, or ethanol 
control. Western blot analysis was performed as described (Rahkola-Soisalo 
et al. 2013) with some modifications. Of the HUVEC lysates, an aliquot of 
3.75 μg of protein was used for gel electrophoresis. Primary antibodies were 
mouse monoclonal anti-eNOS/NOS type III (1:2500; BD Biosciences) and 
anti-eNOS (pS1177) (1:750; BD Biosciences). As a secondary antibody, 
polyclonal rabbit anti-mouse immunoglobulin coupled to horseradish 
peroxidase (DAKO, Glostrup, Denmark) was used. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, 1:20000; Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) served as a protein-loading control. Signal intensity 
was quantified by densitometry (Syngene; Synoptics Limited, Cambridge, 
UK). The results were normalized to the signal intensity of the baseline 
sample on the same membrane. We performed two independent cell culture 
experiments, and three Western blot analyses from each experiment. 
4.2.6 CELLULAR UPTAKE AND HYDROLYSIS OF HDL-ASSOCIATED 
DHEA FATTY ACYL ESTERS (STUDY II) 
HUVECs were purchased from Lonza Group Ltd. (USA) and cultured as 
described in Study II. To examine the uptake of HDL-associated [3H]DHEA 
esters, cells in 6-well plates were treated with [3H]DHEA fatty acyl ester-
enriched HDL in serum-free medium for 0.5, 1, 3, 6, or 24 h. At each time 
point, one well containing no cells served as control. In selected experiments, 
the function of HDL receptor SR-BI was blocked by pretreating the cells or 
media (in control wells) with thiosemicarbazone BLT-1. 
After the incubation, the cell culture media and the control media were 
collected and centrifuged. The cells were washed twice with PBS, and 
intracellular lipids were extracted by treating the cell monolayer with 
hexane/isopropanol (2:3, v/v) for 1 h at room temperature. The intracellular 
lipid extract was evaporated and stored in methanol. The cell remnants were 
lysed with sodium hydroxide, and the protein concentration was measured. 
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To study the metabolism of DHEA fatty acyl esters in HUVECs, the cells 
and media (in control wells) were incubated with [3H]DHEA fatty acyl ester-
enriched HDL for 6 h, after which the media were removed, and the cells 
were washed twice with PBS. After changing fresh culture media without 
[3H]DHEA ester-HDL, the cells were cultured for additional 12 h or 36 h. The 
cells and media were then collected and processed as described above. 
The radioactivity in media and cellular fractions was measured by liquid 
scintillation counting. The [3H]-labeled steroids were extracted from the 
media with ethyl acetate/diethyl ether (1:1, v/v), evaporated and dissolved in 
methanol. The distribution of [3H]DHEA and [3H]DHEA fatty acyl esters in 
the cells and the media was analyzed by TLC as described in the section 
4.2.3. 
4.2.7 STEROID SULFATASE ACTIVITY ASSAY IN ADIPOSE TISSUE 
(STUDY III) 
Radiolabeled DHEAS was used as a substrate to study the activity of steroid 
sulfatase in adipose tissue. Paired subcutaneous and visceral adipose tissue 
samples (200 mg each) were homogenized in distilled water on ice. Purified 
[3H]DHEAS (Fotsis 1987) in ethanol was added to the tissue homogenate, 
and the mixture was incubated at +37 °C for 3 h. To observe the hydrolysis of 
[3H]DHEAS as a function of time, [3H]DHEAS was incubated with pooled 
subcutaneous and visceral adipose tissue homogenate for 0, 1, 2, 3, 6, and 
24 h at +37 °C. Incubations of [3H]DHEAS with water served as controls. 
After the incubation period, the mixture was extracted with diethyl ether, 
evaporated, dissolved in 1 ml of hexane, and subjected to Sephadex LH-20 
chromatography (column dimension 1 × 6 cm) to purify [3H]DHEA formed 
during the incubation. The hydrophobic fraction was eluted with 8 ml of 
hexane, after which the column was washed with 6 ml of hexane, and the 
DHEA fraction was eluted with 17 ml of chloroform/hexane (1:1, v/v). The 
radioactivity in the DHEA fraction was measured by liquid scintillation 
counting. 
4.2.8 QUANTITATIVE REAL-TIME RT-PCR (STUDY III) 
The mRNA expression levels of six steroid-metabolizing enzymes, namely 
steroid sulfatase (STS), hormone-sensitive lipase (LIPE), aromatase 
(CYP19A1), and 17βHSD types 1, 7, and 12 (HSD17B1, HSD17B7, HSD17B12) 
in adipose tissue were quantified by real-time RT-PCR as previously 
described (Wang F et al. 2013). Briefly, frozen adipose tissue samples were 
homogenized in Trizol, and total RNA was isolated and purified. RNA was 
reverse transcribed into cDNA, and mRNA expression levels of the six target 
genes were analyzed by quantitative real-time RT-PCR. The efficiency ranged 
between 93% and 114%. The results were normalized to the geometric mean 
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of the two most stable control genes, importin 8 (IPO8) and lysine (K)-
specific demethylase 2B (KDM2B). 
4.2.9 QUANTIFICATION OF SERUM HORMONES (STUDY III) 
Quantification methods for serum DHEAS, DHEA, estrone, and estradiol 
concentrations by liquid chromatography−tandem mass spectrometry are 
described in the original Study III. 
4.2.10 OTHER METHODS 
Serum follicle-stimulating hormone (FSH) and SHBG were measured with 
commercial methods described in Study III. 
4.2.11 STATISTICAL ANALYSES 
Statistical analyses were carried out with SPSS software (versions 15.0, 17.0, 
and 22.0). Data from arterial relaxation experiments (Studies I and II) are 
presented as mean±standard error of the mean (SEM). Differences in mean 
relaxation responses were tested by ANOVA followed by Sheffe’s post hoc 
test, or by independent-samples t-test when comparing two groups. In Study 
III, the data are expressed as median (range or interquartile range). The 
Mann-Whitney U test was performed for between-group differences, and the 
Wilcoxon signed rank test for pairwise comparisons. Correlation analyses 
were performed using Spearman’s nonparametric correlation. The level of 
significance was P<0.05. When multiple correlation analyses between 
hormone concentrations and gene expression levels were carried out, the 
correlations were considered significant at P<0.01. The unpublished data are 
presented as mean±SEM, and the differences were tested by ANOVA 
followed by Sheffe’s post hoc test, or by independent-samples t-test. 
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5 RESULTS 
5.1 FORMATION OF DHEA FATTY ACYL ESTERS IN 
HUMAN PLASMA (STUDY I) 
To study whether DHEA becomes incorporated in lipoproteins, [3H]DHEA 
was incubated with human plasma, after which lipoproteins were isolated 
and purified. Of the radioactivity recovered in the lipoprotein fractions, 2% 
was in VLDL fraction, 39% in LDL, and 59% in HDL. The radioactivity 
coincided with the protein in purified lipoprotein fractions, indicating that 
[3H]DHEA was associated with lipoproteins (Figure 3). When the plasma 
incubation was carried out in the presence of LCAT inhibitor DTNB, almost 
no radioactivity was recovered in the lipoprotein fractions, suggesting that 
fatty acyl esterification via LCAT function is required for DHEA to become 
associated with lipoproteins (Figure 3). 
After the purification with Sephadex G25, the lipoprotein-containing 
fractions from the incubation without DTNB were further analyzed by TLC. 
Part of each sample was saponified in order to hydrolyze DHEA fatty acyl 
esters formed during the incubation. Of the radioactivity in the 
nonhydrolyzed HDL and LDL samples, 95% and 92%, respectively, recovered 
in the same position with the DHEA fatty acyl ester standard, confirming 
that DHEA was associated with lipoproteins in esterified form. The 
hydrolyzed samples comigrated with the DHEA standard. 
 
Figure 3. Radioactivity elution pattern of plasma HDL (A) and LDL (B) after chromatography 
on Sephadex G25. [3H]DHEA was incubated with plasma for 4 h in the presence 
(○) and absence (●) of LCAT inhibitor DTNB, followed by isolation and purification 
of lipoproteins. Arrows indicate the fractions where HDL and LDL particles elute. 
Study I. 
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5.2 ARTERIAL RESPONSES IN VITRO (STUDIES I AND 
II) 
5.2.1 ARTERIAL RESPONSES TO DHEA AND ESTRADIOL 
DHEA and estradiol caused a dose-dependent relaxation in isolated rings of 
rat mesenteric arteries. The relaxation response to DHEA was stronger than 
the response to estradiol at the concentration of 100 nmol/l or higher 
(Figure 4). 
 
Figure 4. Relaxation responses to DHEA and estradiol (E2) in isolated rat arterial rings. 
Endothelium-intact rings were precontracted with noradrenaline, and the relaxation 
responses were measured after adding increasing doses (1 nmol/l–100 μmol/l) of 
DHEA (n=11) or E2 (n=10). The data are expressed as mean±SEM. *P<0.05, 
**P<0.01, comparison DHEA vs. E2 (Independent-samples t-test). Study I. 
5.2.2 ARTERIAL RESPONSES TO STEROID FATTY ACYL ESTER-
ENRICHED HDL AND NATIVE HDL 
To explore the possibility that DHEA fatty acyl esters contained in HDL 
could modify the vasodilatory effect of HDL, precontracted rat arterial rings 
were treated with increasing doses of HDL obtained after the incubation of 
DHEA with plasma. This DHEA fatty acyl ester-enriched HDL caused a dose-
dependent relaxation, which was significantly stronger than the relaxation 
response to native HDL obtained from the plasma incubation with the 
vehicle (maximal relaxation responses 43% vs. 25%, P<0.001) (Figure 5A). 
HDL isolated after the incubation of DHEA with plasma in the presence of 
LCAT inhibitor DTNB caused a dose-dependent relaxation (maximal 25%), 
which was weaker than the response to DHEA fatty acyl ester-enriched HDL 
(P<0.001) and did not differ from the response to native HDL (P=0.98) 
(Figure 5A). 
Experiments with HDL enriched with fatty acyl esterified estradiol were 
also carried out as this steroid is generally regarded as a potent vasodilator. 
HDL obtained after the incubation of estradiol with plasma caused a dose-
dependent relaxation, which was significantly stronger than the response to 
-9 -8 -7 -6 -5 -4
0
20
40
60
80
100
Concentration / log (M)
Ar
te
ria
l r
el
ax
at
io
n 
% DHEA
E2**
**
*
**
 41 
native HDL at the HDL total protein concentrations of 1, 10, and 40 μg/ml, 
but not at the maximal concentration of 125 μg/ml (maximal relaxation 
responses 33% vs. 25%, P=0.062) (Figure 5B). 
 
Figure 5. Relaxation responses to HDL in isolated endothelium-intact rat mesenteric arterial 
rings. The rings were precontracted with noradrenaline, and the relaxation 
responses to increasing doses of HDL (0.1–125 μg/ml) were measured. (A) 
Relaxation response to HDL isolated after plasma incubation with 10 μmol/l DHEA 
(DHEA fatty acyl ester-enriched HDL, DHEA-FAE-HDL), with 10 μmol/l DHEA + 
LCAT inhibitor DTNB, or with the vehicle (Native HDL). (B) Relaxation response to 
HDL isolated after plasma incubation with 10 μmol/l estradiol (E2-FAE-HDL) or with 
the vehicle (Native HDL). The data are expressed as mean±SEM, n=13–24. 
*P<0.05, **P<0.01, compared to native HDL. Study I. 
5.2.3 EFFECT OF BLOCKING NITRIC OXIDE SYNTHASE AND 
FUNCTION OF HDL, ANDROGEN, AND ESTROGEN RECEPTORS 
To examine the mechanism by which DHEA fatty acyl ester-enriched HDL 
causes vasorelaxation, the arterial rings were pretreated with the NOS 
antagonist L-NAME. After the pretreatment, the relaxation response to 
DHEA ester-enriched HDL was significantly weaker than the response 
without pretreatment (maximal 43% vs. 30%, P=0.008) (Figure 6A), 
indicating that the vascular relaxation response was partly mediated by 
eNOS. Pretreatment with L-NAME impaired the relaxation response to 
estradiol ester-enriched HDL, as well (33% vs. 18%, P=0.014) (Figure 6B). 
The response to native HDL was slightly impaired by pretreatment with 
L-NAME (25% vs. 19%), but the difference failed to reach statistical 
significance (P=0.062). 
To study the role of HDL receptor SR-BI in the vasorelaxation induced by 
HDL-associated DHEA fatty acyl esters, the rat arterial rings were pretreated 
with SR-BI inhibitor, BLT-1. This pretreatment markedly reduced the 
relaxation response to DHEA ester-enriched HDL (maximal relaxation 74% 
vs. 18%, P<0.001) (Figure 6C), suggesting that the vasodilation was in 
major part mediated by the SR-BI receptor pathway. Pretreatment with 
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Figure 6. Relaxation responses to HDL in isolated rat mesenteric arterial rings. The rings 
were precontracted with noradrenaline, after which the relaxation responses to 
increasing doses of HDL (0.1–125 μg/ml or 1–125 μg/ml) were measured. (A) and 
(B) Relaxation responses to DHEA fatty acyl ester-enriched HDL (DHEA-FAE-HDL) 
and estradiol fatty acyl ester-enriched HDL (E2-FAE-HDL) without pretreatment and 
after pretreatment with NOS antagonist L-NAME. (C) and (D) Responses to DHEA-
FAE-HDL and native HDL with and without pretreatment with SR-BI inhibitor. 
(E) Response to DHEA-FAE-HDL with and without pretreatment with androgen 
(AR) and estrogen (ER) receptor inhibitors. Data are expressed as mean±SEM. 
*P<0.05, **P<0.01, pretreated vs. without pretreatment. Studies I and II. 
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BLT-1 also impaired the relaxation response to native HDL (56% vs. 14%, 
P=0.001) (Figure 6D). 
We further studied the possibility that vasodilation caused by DHEA fatty 
acyl ester-enriched HDL could be mediated through conversion of DHEA to 
androgens or estrogens, and thus through androgen or estrogen receptors. 
Pretreatment with bicalutamide, an androgen receptor antagonist, did not 
affect the vasorelaxation response to DHEA ester-enriched HDL 
(Figure 6E). Blocking of estrogen receptors α and β by preincubation with 
ICI 182,780, which is also an agonist of G protein-coupled estrogen receptor 
(Meyer et al. 2009), enhanced the vasorelaxation response to DHEA ester-
enriched HDL slightly but nonsignificantly (Figure 6E). 
5.3 PHOSPHORYLATION OF ENDOTHELIAL NITRIC 
OXIDE SYNTHASE IN ENDOTHELIAL CELLS 
(UNPUBLISHED) 
To further explore the mechanisms by which DHEA fatty acyl ester-enriched 
HDL causes arterial relaxation, we studied in cultured endothelial cells 
whether these HDL particles increase the phosphorylation degree of eNOS. 
Treatment of the cells with DHEA ester-enriched HDL increased serine-1177-
phosphorylated eNOS at the maximum 9.2-fold compared to the PBS control 
(Figures 7 and 8A). However, this effect did not significantly differ from the 
eNOS phosphorylation caused by native HDL (9.0-fold compared to the 
control). A 60-min treatment with free DHEA without HDL caused a 2.2-fold 
increase in phosphorylated eNOS compared to the ethanol control 
(Figure 8A). Total eNOS signal remained unchanged (Figures 7 and 8B) 
(Paatela H et al. unpublished results). 
 
Figure 7. A representative Western blot analysis of eNOS in endothelial cells. HUVECs were 
treated with native HDL, DHEA fatty acyl ester-enriched HDL (DHEA-FAE-HDL), or 
PBS (control). HDL total protein concentration during incubation was 100 µg/ml. 
Cell lysates were analyzed by Western blot using monoclonal antibodies against 
serine-1177-phosphorylated eNOS (p-eNOS) and total eNOS.  
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Figure 8. Protein levels of eNOS in HUVECs. (A) Serine-1177-phosphorylated eNOS 
(p-eNOS). (B) Total eNOS. HUVECs were treated with native HDL, DHEA fatty acyl 
ester-enriched HDL (DHEA-FAE-HDL), or PBS (control). To study the effect of free 
DHEA, cells were treated with 100 nmol/l DHEA or ethanol (control) for 60 min. Cell 
lysates were analyzed by Western blot, followed by densitometric analysis. The 
NOS scales represent density in arbitrary units relative to PBS or ethanol control. 
The data are expressed as mean+SEM, n=5–6. *P≤0.01 compared to PBS control 
(ANOVA and Sheffe’s post hoc test), #P=0.014 compared to ethanol control 
(Independent-samples t-test). 
5.4 CELLULAR UPTAKE AND HYDROLYSIS OF HDL-
ASSOCIATED DHEA FATTY ACYL ESTERS 
(STUDY II) 
We further explored whether the vasodilatory effect of DHEA ester-enriched 
HDL could be mediated by rapid cellular uptake and hydrolysis of DHEA 
fatty acyl esters transported by HDL. This possible mechanism was studied 
in cultured human endothelial cells. HDL enriched with [3H]DHEA fatty acyl 
esters was prepared by incubating [3H]DHEA with pooled female plasma, 
followed by isolation and purification of HDL. HUVECs were treated with 
this [3H]DHEA ester-enriched HDL, and after the incubation period, 
intracellular and extracellular radioactivity was analyzed. Intracellular 
radioactivity increased as a function of time to the maximum of 1.3% of total 
radioactivity (Figure 9A). To investigate whether DHEA fatty acyl esters are 
hydrolyzed after the internalization, the intracellular and extracellular 
radioactivity was further analyzed by TLC. Intracellularly, the proportion of 
free, unesterified [3H]DHEA was relatively stable up to 6 h, but then 
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Figure 9. Uptake and hydrolysis of HDL-associated [3H]DHEA fatty acyl esters in HUVECs. 
(A) Uptake of HDL-associated [3H]DHEA by HUVECs as a function of time. Cells 
were incubated with [3H]DHEA fatty acyl ester-enriched HDL (HDL protein 100 
μg/ml), and intracellular radioactivity was measured. Intracellular radioactivity is 
expressed as a percentage of the total radioactivity in cells and medium 
(mean±SEM). (B) Radioactivity in unesterified DHEA fraction in TLC analysis. Cells 
or control media without cells were incubated with [3H]DHEA ester-enriched HDL, 
after which media and cells were extracted, and subjected to TLC. Data are 
expressed as a percentage radioactivity in unesterified DHEA fraction of the total 
radioactivity recovered. Study II. 
increased from 1.6% up to 3.4% between 6- and 24-h incubations 
(Figure 9B). Similarly to what was observed in the intracellular 
compartment, in the cell culture media, the proportion of free [3H]DHEA 
increased between 6 and 24 h from 1.2% to 3.4% (Figure 9B). In the control 
wells, containing media and [3H]DHEA ester-enriched HDL but no cells, the 
proportion of free [3H]DHEA remained relatively stable, indicating that 
[3H]DHEA esters were not spontaneously hydrolyzed (Figure 9B). 
We next studied the role of SR-BI in the internalization of HDL-
associated DHEA fatty acyl esters. Treatment of the endothelial cells with 
SR-BI inhibitor BLT-1 prior to exposure to [3H]DHEA fatty acyl ester-
enriched HDL inhibited cellular uptake of [3H]DHEA esters by 20–38% 
(Figure 10A). After 24-h incubation, the proportion of unesterified DHEA 
in the cell culture medium, analyzed by TLC, was 7.2% of the recovered 
radioactivity, but decreased to 2.1% when the cells were pretreated with 
BLT-1 (Figure 10B). Thus, this pretreatment inhibited the secretion of free 
DHEA, after the intracellular hydrolysis of DHEA esters, from the cells more 
than the uptake of DHEA esters. 
We further studied the metabolism of DHEA fatty acyl esters after the 
uptake by HUVECs. Cells were incubated with [3H]DHEA ester-enriched 
HDL for 6 h, after which the media were changed and the cells were cultured 
for additional 12 and 36 h. At these time points, the distribution of [3H] was 
analyzed by TLC. In the cells, the proportion of [3H]DHEA fatty acyl esters 
decreased and free [3H]DHEA markedly increased from 12 to 36 h 
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(Figure 11). In the cell culture media, at these time points, the radioactivity, 
representing secretion of [3H]-labeled steroids by the cells, recovered mostly 
in the free, unesterified steroid fraction (Figure 11). Part of the radioactivity 
in the media was recovered near the sample application point on the TLC 
plate, suggesting that the cells had secreted unidentified hydrophilic 
metabolites of [3H]DHEA. 
 
Figure 10. Effect of blocking SR-BI function on uptake and hydrolysis of HDL-associated 
[3H]DHEA fatty acyl esters in HUVECs. (A) Uptake of HDL-associated [3H]DHEA 
esters as a function of time. Cells were pretreated with SR-BI inhibitor BLT-1 prior 
to incubation with [3H]DHEA ester-enriched HDL (HDL protein 100 μg/ml). After the 
incubation, intracellular radioactivity was measured. Intracellular radioactivity is 
expressed as a percentage of the total radioactivity in cells and medium. (B) Cells 
or control media without cells were pretreated with BLT-1 and then incubated with 
[3H]DHEA ester-enriched HDL. After the incubation, media were extracted and 
subjected to TLC. Data are expressed as a percentage radioactivity in unesterified 
DHEA fraction of the total radioactivity recovered. Study II. 
 
Figure 11. Radioactivity as percentage distribution in HUVECs and culture media. HUVECs 
were incubated with [3H]DHEA fatty acyl ester-enriched HDL for 6 h. After changing 
fresh medium without [3H]DHEA ester-HDL, the cells were incubated for additional 
12 or 36 h, and media and cells were extracted and subjected to TLC. Study II. 
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5.5 ACTIVITY OF STEROID SULFATASE AND GENE 
EXPRESSION OF STEROID-CONVERTING ENZYMES 
IN ADIPOSE TISSUE (STUDY III) 
5.5.1 SERUM HORMONE CONCENTRATIONS 
Concentrations of DHEAS, DHEA, estrone, and estradiol in serum obtained 
from 18 premenopausal and seven postmenopausal women undergoing 
elective surgery are shown in Table 2. All these hormone concentration were 
higher in premenopausal than in postmenopausal women, and the 
concentrations correlated negatively with age (DHEAS, r=−0.581; DHEA, 
r=−0.719; estrone, r=−0.513; estradiol, r=−0.467; P<0.05 for all; n=25). 
Serum DHEA correlated positively with serum DHEAS in premenopausal 
(r=0.734, P=0.001, n=18), in postmenopausal (r=0.893, P=0.007, n=7), and 
in all women analyzed together (r=0.843, P<0.001, n=25). Furthermore, 
serum estradiol correlated with serum estrone in premenopausal (r=0.796, 
P<0.001), postmenopausal (r=1.0, P<0.001), and all women (r=0.898, 
P<0.001). 
Table 2. Serum hormone concentrations. Study III. 
 Premenopausal Postmenopausal  
 n=18 n=7 P valuea 
DHEAS, μmol/l 3.7 (1.2−7.1) 1.5 (0.2−4.2) 0.025 
DHEA, nmol/l 14.1 (1.9−58.0) 4.7 (0.2−20.5) 0.012 
Estrone, pmol/l 228 (122−970) 94 (15−216) 0.001 
Estradiol, pmol/l 339 (33−1342) 42 (9−358) 0.005 
The data are expressed as median (range). 
aComparison premenopausal vs. postmenopausal (Mann-Whitney U Test). 
5.5.2 STEROID SULFATASE ACTIVITY IN ADIPOSE TISSUE 
To investigate steroid sulfatase activity in adipose tissue, radiolabeled 
DHEAS was used as the substrate, and the conversion of [3H]DHEAS to 
[3H]DHEA during the incubation in the presence of adipose tissue sample 
was determined. The hydrolysis of [3H]DHEAS in pooled subcutaneous and 
visceral adipose tissue homogenate increased as a function of time up to 24 h 
(Figure 12A). Based on this assay, we chose the 3-h incubation time for 
further experiments. Next, we incubated [3H]DHEAS in the presence of 
homogenized subcutaneous or visceral adipose tissue derived from pre- and 
postmenopausal women, and observed the conversion of [3H]DHEAS to 
[3H]DHEA. Steroid sulfatase activity was higher in postmenopausal than in 
premenopausal women both in subcutaneous (median 379 vs. 257 pmol 
converted to [3H]DHEA/kg adipose tissue per hour; P=0.006) and in visceral  
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(545 vs. 360 pmol/kg/hour; P=0.004) adipose tissue (Figure 12B). In 
visceral adipose tissue, steroid sulfatase activity was higher compared to the 
activity in subcutaneous adipose tissue. This difference was significant in 
premenopausal (P=0.035) and all women (475 vs. 303 pmol/kg/hour, 
P=0.010), but not in postmenopausal women (P=0.128) (Figure 12B). In 
premenopausal women and in all women analyzed together, DHEA sulfatase 
activity in subcutaneous fat correlated positively with the activity in visceral 
fat (premenopausal, r=0.472, P=0.048; all, r=0.571, P=0.003). Steroid 
sulfatase activity in both adipose tissue depots correlated positively with age 
(visceral, r=0.416, P=0.039; subcutaneous, r=0.604, P=0.001) in all women 
analyzed together. However, when premenopausal and postmenopausal 
women were analyzed separately, no positive correlation was found between 
sulfatase activity and age. Steroid sulfatase activity did not correlate with 
serum DHEAS or DHEA concentrations in any of the study groups. 
 
Figure 12. Hydrolysis of DHEAS in adipose tissue. (A) Conversion of [3H]DHEAS to [3H]DHEA 
as a function of time. [3H]DHEAS was incubated in the presence or absence 
(control) of homogenized, pooled subcutaneous and visceral adipose tissue 
samples, followed by extraction, purification, and quantification of [3H]DHEA. Data 
are expressed as a percentage of [3H]DHEAS converted to [3H]DHEA. (B) Steroid 
sulfatase activity in subcutaneous (Sc) and visceral (Visc) adipose tissue. 
[3H]DHEAS was incubated with fat tissue homogenate for 3 h, followed by 
extraction, purification, and quantification of [3H]DHEA. The hydrolysis is expressed 
as the amount of liberated [3H]DHEA (pmol)/adipose tissue (kg)/incubation time (h). 
Data are expressed as median (interquartile range). Premenopausal, n=18; 
Postmenopausal, n=7. #P<0.01, pre- vs. postmenopausal (Mann-Whitney U Test). 
*P<0.05, subcutaneous vs. visceral fat (Wilcoxon Signed Rank Test). Study III. 
5.5.3 GENE EXPRESSION OF STEROID-CONVERTING ENZYMES IN 
ADIPOSE TISSUE 
The relative mRNA expression of STS gene in adipose tissue was similar in 
premenopausal and postmenopausal women (Figure 13). STS displayed, 
however, higher expression in subcutaneous than in visceral adipose tissue. 
This difference was significant in premenopausal (P=0.001) and in all 
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Figure 13. Relative mRNA expression levels of steroid-converting genes in abdominal 
subcutaneous (Sc) and visceral (Visc) adipose tissue derived from pre- and 
postmenopausal women. STS, steroid sulfatase; LIPE, hormone-sensitive lipase; 
CYP19A1, aromatase; HSD17B1, HSD17B7, HSD17B12, 17β-hydroxysteroid 
dehydrogenase types 1, 7, and 12. Data are presented as median (interquartile 
range). #P≤0.01, pre- vs. postmenopausal (Mann-Whitney U Test). *P<0.01, 
comparison of the expression of the same gene in subcutaneous vs. visceral fat 
(Wilcoxon Signed Rank Test). Study III. 
women (P<0.001), but nonsignificant in postmenopausal women (P=0.080) 
(Figure 13). 
In addition to STS gene, we quantified gene expression levels of some 
steroid-converting enzymes that drive towards the formation of active 
estradiol. The mRNA expression levels of CYP19A1 and HSD17B12 were 
higher in postmenopausal compared to premenopausal subcutaneous 
adipose tissue. Similarly in visceral adipose tissue, the expression of LIPE 
gene was higher in postmenopausal than in premenopausal women 
(Figure 13). In comparison between the two adipose tissue depots, the 
expression levels of LIPE and CYP19A1 were higher in subcutaneous adipose 
tissue in premenopausal (Figure 13) and all women (LIPE, P=0.004; 
CYP19A1, P=0.001), and the expression of HSD17B7 was higher in visceral 
adipose tissue in premenopausal (Figure 13) and all women (P<0.001). We 
found no measurable mRNA expression of estrogen sulfotransferase gene 
(SULT1E1) in adipose tissue. 
The DHEA sulfatase activity correlated positively with the mRNA 
expression levels of STS, CYP19A1, and HSD17B12 in subcutaneous adipose 
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tissue in all women analyzed together (Table 3). In visceral adipose tissue, 
the sulfatase activity correlated with CYP19A1 gene expression (Table 3). 
In postmenopausal women, the STS mRNA expression in subcutaneous 
and visceral adipose tissue correlated strongly with serum estrone and 
estradiol concentrations (Table 4). Serum DHEAS and DHEA 
concentrations displayed, however, no correlation with the mRNA expression 
levels of any of the genes studied. 
The mRNA expression of CYP19A1 in subcutaneous adipose tissue 
correlated positively with waist-to-hip ratio in premenopausal (r=0.574, 
P=0.016) and all women (r=0.541, P=0.008), and the expression of the same 
gene in visceral fat displayed a positive correlation with body mass index 
(r=0.886, P=0.019) and waist-to-hip ratio (r=0.829, P=0.042) in 
postmenopausal women. 
 
Table 3. Correlations between steroid sulfatase activity and mRNA expression levels of 
steroid-converting genes in adipose tissue. Study III. 
 STS LIPE CYP19A1 HSD17B1 HSD17B7 HSD17B12 
Sulfatase activity       
Subcutaneous 0.412* 0.045 0.694** -0.013 0.118 0.536** 
Visceral 0.042 -0.059 0.414* 0.242 0.269 0.319 
Correlation coefficients between the corresponding variables are expressed in the table 
(Spearman’s correlation). All women (n=24) analyzed together. 
*P<0.05, **P<0.01, Statistically significant correlations are in bold. 
 
Table 4. Correlations between serum estrogen concentrations and adipose tissue 
mRNA expression of steroid sulfatase (STS) in postmenopausal women. 
Study III.  
Serum hormone Subcutaneous STS mRNA Visceral STS mRNA 
 r P-value r P-value 
Estrone 0.943 0.005 0.943 0.005 
Estradiol 0.943 0.005 0.943 0.005 
r, correlation coefficient (Spearman’s correlation). n=6.  
Statistically significant correlations are in bold. 
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6 DISCUSSION 
6.1 INCORPORATION OF DHEA FATTY ACYL ESTERS 
IN PLASMA LIPOPROTEINS 
During the incubation with human plasma, [3H]DHEA became fatty acyl 
esterified and associated with lipoproteins (I), which is in line with previous 
studies (Leszczynski et al. 1989, Roy and Bélanger 1993, Lavallée et al. 
1996a). The esterification of DHEA occurs in HDL3 subfraction (Leszczynski 
et al. 1989, Leszczynski and Schafer 1991), and from these particles, 
lipophilic DHEA fatty acyl esters can be transferred to other lipoprotein 
particles (Roy and Bélanger 1989, Provost et al. 1997). In our study, after the 
4-hour incubation of [3H]DHEA with plasma, [3H]DHEA fatty acyl esters 
were found in HDL, LDL, and VLDL fractions, suggesting that DHEA esters 
had been transferred from HDL to other lipoproteins. Consistent with 
previous studies (Roy and Bélanger 1989, Lavallée et al. 1996a), the 
esterification was dependent on LCAT. The radioactivity associated with 
HDL and LDL was almost exclusively (92-95%) in DHEA fatty acyl esterified 
form, similarly to a previous finding that approximately 90% of DHEA in 
lipoprotein fractions after 6-hour plasma incubation was in lipophilic form 
(Roy and Bélanger 1989). In our study, when LCAT inhibitor DTNB was 
present in the incubation, almost no radioactivity was associated with 
lipoproteins, indicating that esterification is required for the incorporation of 
DHEA in the lipoproteins. DHEA becomes esterified in plasma at much 
higher rate than estradiol (Jones and James 1985). In comparison with a 
previous study by our group (Helisten et al. 2001), determining esterification 
of estradiol during 24-hour plasma incubation, we now observed in HDL 
fraction approximately four times higher amounts of esterified DHEA 
compared to esterified estradiol in the previous study, the amounts of DHEA 
and estradiol added to the plasma being equal. 
6.2 VASODILATORY EFFECTS OF DHEA AND 
ESTRADIOL 
On the vascular endothelium, both DHEA and estradiol rapidly activate 
eNOS, thus resulting in the production of nitric oxide (Simoncini et al. 2003, 
Chambliss and Shaul 2002), a potent vasodilator. We aimed to confirm the 
rapid vasodilatory effects of DHEA and estradiol in our experimental system 
in isolated rings of rat mesenteric arteries and to compare the relaxation 
responses to these two steroids. Both DHEA and estradiol caused a dose-
dependent relaxation in the arterial rings (I). DHEA induced a stronger 
vasodilation compared to estradiol. Both steroids caused the arterial 
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relaxation at rather high concentrations. The lowest concentration of 
estradiol causing a significant (20%) relaxation was 10 μmol/l, which is a 
clearly supraphysiological concentration. With DHEA, approximately similar 
relaxation response (24%) was achieved at the concentration of 1 μmol/l, also 
a supraphysiological concentration (Labrie et al. 2011). Based on these 
relaxation responses ex vivo and the fact that DHEA is circulating at higher 
concentrations than estradiol, our present findings suggest that circulating 
DHEA could be a more efficient vasodilator compared to estradiol. 
6.3 VASCULAR EFFECTS OF HDL-ASSOCIATED 
STEROID FATTY ACYL ESTERS 
6.3.1 ENHANCEMENT OF VASODILATORY EFFECTS OF HDL 
Both HDL particles and DHEA have been shown to increase endothelial 
nitric oxide production and cause rapid vasodilation (Yuhanna et al. 2001, 
Liu and Dillon 2002, Simoncini et al. 2003, Liu and Dillon 2004). This led us 
to ask whether HDL-associated DHEA fatty acyl esters could improve the 
vasodilatory effect of HDL. In isolated rings of rat mesenteric arteries, we 
demonstrated that HDL enriched with DHEA fatty acyl esters was a more 
potent vasodilator than native HDL (I). DHEA ester-enriched HDL was 
prepared by incubating DHEA with plasma. When identical plasma 
incubation was performed in the presence of LCAT inhibitor, HDL isolated 
after the incubation caused significantly weaker vasodilation compared to 
DHEA fatty acyl ester-enriched HDL, and the relaxation response did not 
differ from the response to native HDL (I). This finding indicates that the 
esterification of DHEA is required for the improvement of the vasodilatory 
response.  
Steroid fatty acyl esters are lipophilic and thus incorporated in the 
lipoprotein particles in the circulation (Roy and Bélanger 1993, Vihma et al. 
2003a). The biological role of lipoprotein-associated steroid fatty acyl esters 
is not fully understood. HDL has several antiatherogenic properties, which 
are thought to be dependent on its functionality (Vickers and Remaley 2014, 
Kontush 2014). HDL particles are heterogeneous in their composition and 
function, and in the circulation they transport numerous different cargos. 
These cargo-substances are biologically important for the functionality of 
HDL (Vickers and Remaley 2014). Steroid fatty acyl esters are endogenous 
cargos of HDL. Our finding that DHEA fatty acyl esters in HDL enhanced the 
vasodilatory capacity of HDL (I) suggests that these cargos may have 
relevance in the vascular effects of HDL. Hence, DHEA fatty acyl esters may 
improve antiatherogenic function of HDL. However, we used 
supraphysiological concentrations (10 μmol/l) of DHEA during the plasma 
incubation, and thus HDL presumably contained higher than normal DHEA 
fatty acyl ester concentrations. In addition to DHEA esters synthesized 
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during the incubation, isolated HDL particles contained an unknown amount 
of endogenous DHEA esters present in female HDL, as did also the native 
HDL. 
HDL enriched with estradiol fatty acyl esters also caused a dose-
dependent relaxation, which was significantly stronger than the relaxation 
caused by native HDL at the HDL protein concentrations of 1, 10, and 40 
μg/ml, but not with the largest dose 125 μg/ml (I). The relaxation response 
to estradiol ester-enriched HDL was not as strong as the response to DHEA 
ester-enriched HDL. However, DHEA becomes esterified and associated with 
lipoproteins at much higher rate than estradiol (Jones and James 1985, 
Helisten et al. 2001), and thus direct comparisons between the HDLs 
enriched with DHEA esters and estradiol esters are difficult to make. 
Previous work by Gong and co-workers (2003) suggests that HDL-
associated estradiol may play a role in eNOS activation and vasodilation 
caused by HDL. They demonstrated that HDL from female but not from male 
mice caused vasodilation in isolated mouse arterial rings. HDL from 
premenopausal women and postmenopausal women receiving estrogen 
therapy induced eNOS activation in endothelial cells, whereas HDL from 
postmenopausal women without estrogen therapy or HDL from men did not 
stimulate eNOS. Furthermore, Gong and co-workers (2003) showed that 
endothelial cells could internalize HDL-associated estradiol. In the HDL 
fractions causing eNOS activation, physiological estradiol concentrations 
were measured. They suggested that estradiol associated with HDL could 
mediate eNOS activation caused by HDL. However, estradiol fatty acyl esters 
were not analyzed, and based on previous studies, estradiol is known to be 
associated with HDL in fatty acyl esterified form (Leszczynski and Schafer 
1991, Höckerstedt et al. 2002, Vihma et al. 2003a). In contrast to the 
findings by Gong et al., Nofer and co-workers (2004) found no difference 
between vasodilatory responses to male and female HDL in mouse aortic 
rings. Our group has previously reported that increased serum estradiol fatty 
acyl ester concentrations during postmenopausal hormone therapy correlate 
positively with enhanced forearm blood flow responses in vivo (Vihma et al. 
2003b). Our present finding of slightly enhanced vasodilation by estradiol 
fatty acyl ester-enriched HDL together with our previous findings in vivo 
(Vihma et al. 2003b) suggest that estradiol fatty acyl esters may also 
contribute to the vasodilatory function of HDL. 
Another cargo of HDL, namely sphingosine-1-phosphate (S1P), induces 
vasodilation, and the vasodilatory effect of HDL is proposed to be partly 
mediated by S1P (Nofer et al. 2004, Roviezzo et al. 2006, Egom et al. 2013). 
Hence, there are many cargos, including steroid fatty acyl esters and S1P, 
which may contribute to the positive effects of HDL on endothelial function 
independent of the plasma HDL cholesterol level. The protective effect of 
HDL against cardiovascular disease may depend on these and other cargos 
influencing the functionality of HDL.  
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6.3.2 RECEPTORS INVOLVED IN DHEA FATTY ACYL ESTER-
INDUCED VASODILATION 
HDL enriched with DHEA fatty acyl esters induced relaxation in isolated rat 
arterial rings via the SR-BI receptor pathway (II). Also native HDL caused 
vasodilation through SR-BI (II), consistent with previous studies. HDL 
binding to SR-BI is known to enhance eNOS activity and endothelium-
dependent vasodilation (Yuhanna et al. 2001). In the endothelium, SR-BI 
and eNOS are colocalized in specific plasma membrane domains called 
caveolae (Uittenbogaard et al. 2000, Yuhanna et al. 2001). HDL activates, in 
SR-BI-mediated pathway, complex cellular signaling cascades leading to the 
phosphorylation of eNOS at serine-1177, which activates the enzyme (Mineo 
et al. 2003). Simultaneous cholesterol flux is required for the signal initiation 
by HDL–SR-BI interaction (Saddar et al. 2010). By inhibiting SR-BI-
mediated lipid transport with a potent inhibitor, BLT-1, the relaxation 
response to DHEA ester-enriched HDL was dramatically attenuated (II). 
This led us to hypothesize that HDL-incorporated DHEA fatty acyl esters 
could be internalized by endothelial cells through SR-BI-mediated selective 
uptake and hydrolyzed to free DHEA, a potent vasodilator. In cultured 
human endothelial cells, we showed that HDL-associated DHEA fatty acyl 
esters were internalized partly via SR-BI, and after the internalization DHEA 
fatty acyl esters were hydrolyzed generating free DHEA (II). This process 
was, however, slow, proceeding during several hours, whereas relaxation of 
the arterial rings occurred in minutes. Therefore, it is unlikely that the 
liberated DHEA would be responsible for the rapid vasodilatory action of 
DHEA ester-enriched HDL. 
The vasodilatory effect of DHEA fatty acyl ester-enriched HDL was not 
mediated by androgen or estrogen receptors (II). This indicates that the 
relaxation by DHEA ester-enriched HDL was not facilitated by the 
conversion of DHEA to biologically active androgens or estrogens. This was 
not unexpected, as the relaxation response was very rapid, appearing 
immediately after the addition of DHEA ester-enriched HDL (I, II). Free, 
unesterified DHEA has been shown to rapidly activate eNOS in endothelial 
cells independently of androgen and estrogen receptors (Liu and Dillon 
2002, Simoncini et al. 2003). It has been suggested that DHEA may have a 
specific plasma membrane receptor mediating eNOS activation in vascular 
endothelium (Liu and Dillon 2002, Liu and Dillon 2004). In ovariectomized 
rats with aortic banding-induced pressure overload, DHEA treatment 
enhanced aortic eNOS expression as well as phosphorylation of Akt and 
eNOS through sigma-1 receptor (Bhuiyan et al. 2011). In our study, however, 
the vasodilation was induced by DHEA fatty acyl ester-enriched HDL binding 
to SR-BI (II), and was probably not mediated through conversion of DHEA 
esters to free DHEA. 
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6.3.3 ROLE OF ENDOTHELIAL NITRIC OXIDE SYNTHASE IN DHEA 
FATTY ACYL ESTER-INDUCED VASODILATION 
HDL activates eNOS and nitric oxide production in cultured endothelial cells 
(Yuhanna et al. 2001, Li et al. 2002, Mineo et al. 2003, Nofer et al. 2004). 
Moreover, HDL causes rapid relaxation in isolated aortic rings of rats and 
mice, and pretreatment of the rings with eNOS antagonist L-NAME abolishes 
this effect (Yuhanna et al. 2001, Nofer et al. 2004). In our study, L-NAME 
markedly impaired the relaxation response to DHEA fatty acyl ester-enriched 
HDL, suggesting this response to be partly mediated by eNOS and nitric 
oxide (I). In addition, pretreatment of the arteries with L-NAME weakened 
the vasodilatory effect of native HDL, but the difference did not reach 
statistical significance (I). 
To further explore the role of eNOS in vasodilation caused by DHEA 
ester-enriched HDL, we continued our studies in human vascular endothelial 
cells. We demonstrated that DHEA fatty acyl ester-enriched HDL caused 
serine-1177 phosphorylation of eNOS (Paatela H et al. unpublished results). 
This effect was observed as early as in 5 min and reached the maximum at 10 
min, when the amount of phosphorylated eNOS in the cells treated with 
DHEA ester-enriched HDL was nine times as high as in the cells treated with 
the buffer. Previous studies using endothelial cell cultures have shown that 
HDL activates eNOS through phosphorylation of serine-1177 residue (Mineo 
et al. 2003, Nofer et al. 2004, Kimura et al. 2010). HDL stimulates 
phosphorylation of Akt kinase, which in turn phosphorylates eNOS, leading 
to the activation of the enzyme and production of nitric oxide (Mineo et al. 
2003, Nofer et al. 2004). Phosphorylation of eNOS at serine-1177 and 
parallel activation of MAP kinase pathway have been suggested to be 
required for the activation of eNOS by HDL (Mineo et al. 2003). Consistent 
with the previous studies, we also demonstrated a rapid serine-1177 
phosphorylation of eNOS by native HDL (Paatela H et al. unpublished 
results). In addition, we showed that DHEA ester-enriched HDL caused 
eNOS phosphorylation, supporting the role of eNOS and nitric oxide in the 
vasodilatory effect of DHEA ester-enriched HDL. However, effects of DHEA 
ester-enriched HDL and native HDL on eNOS phosphorylation did not 
significantly differ, and thus the phosphorylation of eNOS in endothelial cells 
does not explain the difference in the arterial relaxation responses caused by 
these HDLs. The semiquantitative Western blot analysis of phosphorylated 
eNOS protein is probably not sensitive enough to detect small differences in 
the phosphorylation state of the enzyme. Furthermore, endothelial cell 
culture is not comparable to the intact arterial rings that contain also smooth 
muscle cells, which are eventually causing the vasodilation. 
There is evidence that HDL has vasodilatory activity not only through 
nitric oxide release, but also through production of prostacyclin (Norata et al. 
2004, Zhang et al. 2012). In addition to the production of nitric oxide, its 
inactivation is an important factor influencing the bioavailability of vascular 
nitric oxide (Förstermann 2010). Furthermore, there are additional eNOS 
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phosphorylation sites, other than serine-1177, that affect eNOS activity 
(Fleming 2010). Increased production of prostacyclin, reduced inactivation 
of nitric oxide, or changes in the phosphorylation state of other residues of 
eNOS could be additional mechanisms for enhanced vasodilatory activity of 
DHEA ester-enriched HDL. These mechanisms, however, were not 
investigated in the present study. 
6.3.4 ENDOTHELIAL UPTAKE AND METABOLISM OF HDL-
ASSOCIATED DHEA FATTY ACYL ESTERS 
In Study II, we demonstrated that human umbilical vein endothelial cells 
internalized HDL-associated DHEA fatty acyl esters. This uptake was partly 
mediated by HDL receptor SR-BI function. Lipoprotein-associated DHEA 
fatty acyl esters are internalized and metabolized by different types of 
cultured cells. Human breast cancer cells have been shown to internalize 
LDL-associated DHEA fatty acyl esters via LDL receptor-mediated uptake 
and to further metabolize DHEA esters to DHEA and androstenediol (Roy 
and Bélanger 1993). In addition, human HeLa cells, derived from 
reproductive tract, are able to internalize LDL-associated DHEA fatty acyl 
esters through LDL receptor or LDL receptor-related receptor pathway, and 
after the internalization, DHEA esters are hydrolyzed and metabolized 
(Wang F et al. 2008). The present study was the first to demonstrate that 
human endothelial cells can internalize lipoprotein-associated DHEA fatty 
acyl esters. A significant proportion of DHEA circulates in fatty acyl esterified 
form incorporated in lipoprotein particles (Roy and Bélanger 1993), and thus 
lipoprotein-transported DHEA fatty acyl esters may be important precursors 
of active hormones in target tissues. Cellular uptake of HDL-associated 
DHEA by endothelial cells could potentially modulate vascular function. 
HDL receptor SR-BI appears to be active in the uptake of HDL-associated 
DHEA fatty acyl esters by endothelial cells, but other routes may participate, 
as well (II). Supporting the role of SR-BI in steroid fatty acyl ester uptake, 
this receptor has been shown to internalize HDL-associated estradiol fatty 
acyl esters in cultured hepatic cells (Badeau RM et al. 2007) and human 
macrophages (Badeau RM et al. 2009). Furthermore, SR-BI participates in 
the uptake of estradiol associated with HDL and LDL by osteoblastic cells 
(Brodeur et al. 2008). 
After the internalization of HDL-associated DHEA fatty acyl esters, 
endothelial cells were able to hydrolyze them. The cells further secreted 
liberated DHEA and unidentified polar metabolites of DHEA to the cell 
culture medium. This was, however, observed after several hours of 
incubation of the cells with DHEA fatty acyl ester-enriched HDL (II). Steroid 
fatty acyl esters are generally regarded as inactive hormone derivatives, 
which need to be hydrolyzed before binding to steroid receptors and exerting 
hormonal actions (Hochberg 1998). Esterases hydrolyzing steroid fatty acyl 
esters are not fully known. Studies in bovine placental and adipose tissue 
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have suggested that hormone-sensitive lipase may be the enzyme hydrolyzing 
estradiol fatty acyl esters (Lee et al. 1988). In human adipose tissue, 
hormone-sensitive lipase hydrolyzes DHEA and cholesteryl esters and is 
partly responsible for the hydrolysis of estradiol fatty acyl esters (Wang F et 
al. 2012). In human HeLa cells, lysosomal acid lipase participates in the 
hydrolysis of DHEA fatty acyl esters, but other unknown esterases are also 
involved (Wang F et al. 2008). Thus, different tissues may have distinct 
steroid fatty acyl ester hydrolyzing activities. Our study demonstrated that 
human endothelial cells were able to hydrolyze DHEA fatty acyl esters (II). 
We further showed that other metabolites of DHEA were secreted from the 
cells (II), suggesting existence of steroid-converting enzyme activity. DHEA, 
as a hormone precursor, can be converted to androgens and estrogens in 
peripheral target tissues (Labrie et al. 2005). Previous studies have shown 
that cultured breast cancer cells can convert LDL-associated DHEA esters to 
DHEA and androstenediol (Roy and Bélanger 1993), and HeLa cells can 
metabolize LDL-associated DHEA esters to DHEA, androstenedione, and 
5α-androstanedione (Wang F et al. 2008). Thus, circulating DHEA fatty acyl 
esters associated with lipoproteins may serve as substrates for peripheral 
steroid hormone synthesis. 
By pretreating the endothelial cells with BLT-1, a potent inhibitor of 
SR-BI-mediated lipid transport, the secretion of free DHEA from the cells 
was markedly reduced (II). This suggests that SR-BI could mediate the flux 
of unesterified DHEA, like that of cholesterol (Mineo and Shaul 2012), from 
endothelial cells. 
Although cultured endothelial cells are not comparable to intact vascular 
endothelium, our data suggest that cellular hydrolysis of DHEA esters by 
endothelial cells is a relatively slow reaction, and thus it is unlikely that the 
liberated DHEA would be responsible for the rapid vasodilatory effect of 
DHEA ester-enriched HDL in the vascular wall. Another possibility is that 
DHEA fatty acyl esters incorporated in the HDL particle somehow modify the 
structure and function of HDL itself and thus enhance its vasodilatory 
capacity. 
6.4 DHEA METABOLISM IN ADIPOSE TISSUE 
After the cessation of ovarian estrogen production, all estrogens are 
synthesized in peripheral tissues from hormone precursors (Labrie 2015). In 
postmenopausal women, adipose tissue is an important source of estrogens. 
Our study demonstrated that steroid sulfatase activity, measured as the 
conversion of DHEAS to DHEA, in subcutaneous and visceral adipose tissue 
was higher in postmenopausal than in premenopausal women (III). This 
suggests that DHEAS, which circulates at much higher concentration than 
any other steroid hormone, could be more efficiently utilized by 
postmenopausal compared to premenopausal adipose tissue. Thus, the 
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hydrolysis of DHEAS in adipose tissue may play a more important role in 
steroid biosynthesis after menopause. 
Adipose tissue expresses all the enzymes necessary for the formation of 
active androgens and estrogens from prohormones DHEA and DHEAS 
(Tchernof et al. 2015, Li et al. 2015). We investigated gene expression of 
some key enzymes related to the formation of estradiol. The mRNA 
expression levels of aromatase (CYP19A1 gene) and 17βHSD type 12 were 
higher in postmenopausal than in premenopausal women in subcutaneous 
adipose tissue. In visceral fat, the mRNA expression of hormone-sensitive 
lipase (LIPE gene) was higher in postmenopausal than in premenopausal 
women. Aromatase is responsible for the conversion of androstenedione to 
estrone and testosterone to estradiol (Forney et al. 1981). Type 12 17βHSD is 
possibly the most important enzyme of the 17βHSD family in converting 
estrone to biologically active estradiol in adipose tissue (Bellemare et al. 
2009). Hormone-sensitive lipase participates in the hydrolysis of DHEA and 
estradiol fatty acyl esters (Wang F et al. 2012). As all these three enzymes 
drive towards the formation of biologically active estradiol, our results are in 
line with the possibility that production of estrogens in adipose tissue could 
be enhanced after menopause. 
Steroid sulfatase activity was higher in visceral than in subcutaneous 
adipose tissue, analyzed in premenopausal women or in all women. There are 
no previous studies comparing sulfatase activity between different adipose 
tissue depots. In fact, steroid sulfatase activity has been previously reported 
only in human subcutaneous adipose tissue (Dalla Valle et al. 2006). 
Accumulation of visceral adipose tissue is related to the development of 
metabolic syndrome, type 2 diabetes, and cardiometabolic and 
cardiovascular complications (Fox et al. 2007, Smith et al. 2012). Sex 
hormones are important regulators of regional fat accumulation (Tchernof 
and Després 2013). Men and women display different body fat distribution 
patterns, and after menopause, visceral adipose tissue increases (Genazzani 
and Gambacciani 2006, Lovejoy et al. 2008, Tchernof and Després 2013). 
Our finding of different DHEA sulfatase activity in subcutaneous and visceral 
adipose tissue depots suggests that body fat distribution may have relevance 
in modulating hormone metabolism, or conversely, local hormone 
metabolism may influence body fat distribution. 
Consistent with previous studies, subcutaneous adipose tissue showed a 
higher mRNA expression of steroid sulfatase, aromatase and hormone-
sensitive lipase compared to visceral adipose tissue. Previous studies in 
adipose tissue obtained from women and obese men have shown that STS 
gene is more expressed in subcutaneous than in visceral fat (Blouin et al. 
2009a, Wang F et al. 2013). Also aromatase mRNA expression is reported to 
be higher in subcutaneous adipose tissue (Wang F et al. 2013), although 
other studies have found only slightly higher expression in subcutaneous 
compared to visceral fat (Blouin et al. 2006, Blouin et al. 2009a). In addition, 
previous studies show that hormone-sensitive lipase displays higher mRNA 
 59 
expression in subcutaneous than in visceral adipose tissue (Ray et al. 2009, 
Wang F et al. 2013) and adipocytes (Reynisdottir et al. 1997). Other studies, 
however, have found no difference in the mRNA expression of hormone-
sensitive lipase in adipose tissue (Lefebvre et al. 1998) or adipocytes 
(Montague et al. 1998) derived from different fat depots. In contrast to 
previous studies (Bellemare et al. 2009, Blouin et al. 2009b, Wang F et al. 
2013), we detected a higher mRNA expression of 17βHSD type 7 in visceral 
than in subcutaneous adipose tissue. Depot-differences in the steroid 
sulfatase activity as well as in the gene expression of steroid-converting 
enzymes found in our study and previous studies suggest that steroid 
hormone synthesis and metabolism may differ between adipose tissue 
depots. 
Steroid sulfatase activity was higher in visceral adipose tissue, whereas 
mRNA expression of STS was higher in subcutaneous fat. Furthermore, 
DHEAS was more efficiently hydrolyzed in postmenopausal than in 
premenopausal adipose tissue, but STS mRNA expression did not differ 
between the groups. These differences may be explained by the possibility 
that steroid sulfatase is regulated by posttranscriptional and 
posttranslational modifications (Mueller et al. 2015). The regulation of 
steroid sulfatase activity has not been studied in adipose tissue. In breast 
cancer cells, inflammatory cytokines have been shown to enhance steroid 
sulfatase activity (Purohit et al. 1996, Newman et al. 2000, Honma et al. 
2002), and this activation occurs without increase in STS mRNA expression 
(Newman et al. 2000). Postmenopausal women have an increased 
inflammatory response in abdominal (Alvehus et al. 2012) and breast 
(Iyengar et al. 2015) subcutaneous adipose tissue. Furthermore, adipose 
tissue distribution influences inflammatory cytokine secretion (Tchernof and 
Després 2013). Our findings of higher sulfatase activity but similar STS 
mRNA expression after menopause could be explained by increased adipose 
tissue inflammation in postmenopause. Inflammatory factors might also 
explain the different profiles of steroid sulfatase activity and mRNA 
expression between adipose tissue depots. 
The mRNA expression levels of the genes studied did not correlate with 
serum concentrations of DHEAS or DHEA. Serum estrone and estradiol, 
however, correlated positively with the adipose tissue STS mRNA expression 
in postmenopausal women. No such correlation was found in premenopausal 
women, as expected due to the fluctuation in serum estrogen levels during 
the menstrual cycle. Our finding suggests that steroid sulfatase in adipose 
tissue may contribute to serum estrogen levels after menopause, when all 
estrogens derive from peripheral tissues. Steroid sulfatase activity did not 
correlate with serum estrogen concentrations. However, we measured steroid 
sulfatase activity by the conversion of DHEAS to DHEA and not by the 
conversion of estrone sulfate to estrone, which might have yielded a different 
result. 
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In all women analyzed together, steroid sulfatase activity correlated 
positively with the mRNA expression levels of steroid sulfatase, aromatase, 
and 17βHSD type 12 in subcutaneous adipose tissue. This raises the 
possibility that enhanced hydrolysis of DHEAS could be related to the 
increased expression of these genes, further directing this pathway towards 
the formation of biologically active estradiol. 
Sulfation and desulfation of steroid hormones are important regulatory 
mechanisms in steroidogenesis and hormone actions in peripheral tissues 
(Mueller et al. 2015). Sulfated steroids, such as DHEAS and estrone sulfate, 
are suggested to act as reservoirs of substrates for the peripheral synthesis of 
biologically active steroid hormones (Mueller et al. 2015). DHEAS 
concentrations in the circulation are reported to be much higher than those 
in adipose tissue (Deslypere et al. 1985), whereas other sex steroids, 
including DHEA, estradiol, and estrone, are more abundant in adipose tissue 
than in serum (Deslypere et al. 1985, Badeau M et al. 2007, Wang F et al. 
2011, Kinoshita et al. 2014, Vihma et al. 2016). Low DHEAS concentrations 
in adipose tissue may be due to active and rapid hydrolysis of this 
hydrophilic derivative in the tissue. Circulating DHEAS can be internalized 
by adipocytes through an active transport, presumably facilitated by OATP 
(Dalla Valle et al. 2006). Our study suggests that adipose tissue could utilize 
DHEAS, derived from the circulation, more efficiently after menopause. 
Thus, more DHEA could be liberated for further conversion to biologically 
active androgens and estrogens. 
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7 SUMMARY, CONCLUSIONS, AND 
FUTURE PERSPECTIVE 
The present thesis aimed at elucidating the role of DHEA in lipophilic 
environment – circulating lipoproteins and adipose tissue. The results can be 
summarized as follows: 
 
1) DHEA was esterified to its fatty acyl ester derivatives, when incubated with 
human plasma, and these lipophilic derivatives were incorporated in plasma 
lipoproteins. 
 
2) DHEA fatty acyl ester-enriched HDL showed a stronger vasodilatory effect 
compared to native HDL in isolated rat arterial rings ex vivo. The 
vasodilatory effect of DHEA ester-enriched HDL was mediated by HDL 
receptor SR-BI, but not through androgen or estrogen receptors. The arterial 
relaxation was in part mediated by eNOS. DHEA ester-enriched HDL and 
native HDL induced rapid eNOS phosphorylation in cultured endothelial 
cells. These results suggest that DHEA fatty acyl esters, associated with HDL 
as cargos, enhance the vasodilatory capacity of HDL and thus may improve 
the antiatherogenic function of HDL. This is a novel biological function for 
lipoprotein-associated steroid fatty acyl esters. 
 
3) Human vascular endothelial cells were able to internalize HDL-associated 
DHEA fatty acyl esters. This uptake was partly mediated by SR-BI. After the 
cellular internalization, DHEA esters were metabolized to DHEA and 
unknown polar metabolites, which were further secreted from the cells. 
These results suggest a role for lipoprotein-associated DHEA fatty acyl esters 
as substrates in peripheral steroid hormone synthesis. Cellular uptake and 
hydrolysis were slow, and thus it is unlikely that the liberated DHEA would 
be responsible for the rapid vasodilatory effect of DHEA ester-enriched HDL. 
 
4) Steroid sulfatase activity, the conversion of DHEAS to DHEA, in 
abdominal subcutaneous and visceral adipose tissue was higher in 
postmenopausal than in premenopausal women. Visceral adipose tissue 
showed a higher sulfatase activity compared to subcutaneous adipose tissue. 
Three genes in the estradiol-producing pathway, aromatase, 17βHSD type 12, 
and hormone-sensitive lipase, were more expressed in postmenopausal 
compared to premenopausal adipose tissue. These results suggest that 
circulating DHEAS could be more efficiently utilized in postmenopausal 
adipose tissue for the formation of biologically active androgens and 
estrogens. Depot-differences in the sulfatase activity and in the gene 
expression of steroid-converting enzymes suggest that steroid hormone 
metabolism may differ between adipose tissue depots. 
Summary, conclusions, and future perspective 
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There are certain aspects to be considered in future research. The HDL-
mediated cardioprotection is thought to be dependent on the functionality of 
HDL and not on the HDL cholesterol level. Hence, the HDL cholesterol 
hypothesis has recently been replaced with the HDL function hypothesis. 
HDL transports numerous biologically active substances, which are 
important for the functionality of HDL. Our study demonstrates that steroid 
hormones, also cargos of HDL, may have relevance in the vasodilatory effect 
of HDL. Thus, they may act as endothelotherapeutic agents enhancing the 
positive effects of HDL. Future studies are crucial to elucidate whether HDL-
associated steroid hormones have influence on other protective effects of 
HDL, including anti-inflammatory, antioxidative, and antithrombotic 
activities. In addition, the mechanisms by which steroid hormones modulate 
the function of HDL need to be further clarified. 
Regarding the role of adipose tissue in the steroid biosynthesis, future 
studies are necessary to clarify to what extent steroid sulfatase hydrolyzes 
estrone sulfate and whether other steroid-converting enzymes in the 
metabolic pathway involved in the formation of androgens and estrogens are 
active in human subcutaneous and visceral adipose tissue. Moreover, of 
special interest would be to elucidate whether biologically active androgens 
and estrogens synthesized in adipose tissue only act locally in the same tissue 
or are transferred to the circulation. 
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